Summary: The mucosal immune system of mammals consists of an integrated network of lymphoid cells which work in concert with innate host factors to promote host defense. Major mucosal effector immune mechanisms include secretory antibodies, largely of immunoglobulin A (IgA) isotype, cytotoxic T cells, as well as cytokines, chemokines and their receptors. Immunologic unresponsiveness (tolerance) is a key feature of the mucosal immune system, and deliberate vaccination or natural immunization by a mucosal route can effectively induce immune suppression. The diverse compartments located in the aerodigestive and genitourinary tracts and exocrine glands communicate via preferential homing of lymphocytes and antigen-presenting cells. Mucosal administration of antigens may result in the concomitant expression of secretory immunoglobulin A (S-IgA) antibody responses in various mucosal tissues and secretions, and under certain conditions, in the suppression of immune responses. Thus, developing formulations based on efficient delivery of selected antigens/tolerogens, cytokines and adjuvants may impact on the design of future vaccines and of specific immunotherapeutic approaches against diseases associated with untoward immune responses, such as autoimmune disorders, allergic reactions, and tissue-damaging inflammatory reactions triggered by persistent microorganisms.

Introduction

The mucous membranes covering the aerodigestive and the urogenital tracts as well as the eye conjunctiva, the inner ear and the ducts of all exocrine glands are endowed with powerful mechanical and physicochemical cleansing mechanisms that degrade and repel most foreign matter. In addition, a large and highly specialized immune system protects these surfaces and thereby also the body interior against potential insults from the environment. In a healthy human adult, this local immune system contributes almost 80% of all immunocytes. These cells are accumulated in or in transit between various mucosal organs and glands and together they form the mucosa-associated lymphoid tissue (MALT), the largest mammalian lymphoid organ system.

The MALT has three main functions: 1) to protect the mucous membranes against colonization and invasion by potentially dangerous microbes encountered; 2) to prevent
uptake of undegraded antigens including foreign proteins derived from ingested food and commensal microorganisms; and 3) to prevent the development of harmful immune responses to these antigens if they do reach the body interior. At variance with the systemic immune apparatus, which functions in a normally sterile milieu and often responds vigorously to invaders, the MALT guards organs that are replete with foreign matter. It follows that upon encounter with this plethora of antigenic stimuli, the MALT must ignore such antigens, or economically select appropriate effector mechanisms and regulate their intensity to avoid bystander tissue damage and immunological exhaustion. Since this system cannot discriminate between pathogenic microorganisms on the one hand, and innocuous matter, such as dietary matter and commensal microorganisms, on the other, it is likely to recognize all foreign peptides. Elucidating the mechanisms that determine whether recognition of such diverse antigens will result in active immunity, immune suppression or ignorance, will have a major impact in the development of effective mucosal vaccines against infectious and inflammatory diseases.

Although the immune apparatus is remarkably diverse, there is strong evidence that certain types of immune responses take place and are basically restricted to certain anatomical locations within the body. The MALT represents a well-known example of such a compartmentalized immunological system. As opposed to the central and peripheral lymphoid organs, the MALT contains inhomogeneously distributed B and T cells whose phenotype, repertoire, developmental origin, secretion products and hence probably also function are different. First, the prime immunoglobulin isotype produced and assembled in mucosal tissues is secretory immunoglobulin A (IgA), which is only present in trace amounts in the intravascular compartment. Further, and although major species differences have been observed, non-conventional lymphocytes rarely seen in other locations, e.g. a/β TCR+CD4-CD8 a-CD8 p- T cells in the gut epithelium. The antigen receptor repertoire is also different in each location. Thus, self-reactive T cells are detected among murine intestinal intraepithelial a/β and γ/δ TCR+ T lymphocytes. Furthermore, in contrast to the T and B lymphocytes found in central and peripheral lymphoid organs, certain γ/δ and a/β T cells found in the mucosa, and presumably also mucosal CD5+ B cells, do not depend on the thymus or bone marrow for their development, respectively. In addition to divergent lineages that are driven to different organs by tissue-specific homing receptors, local selection mechanisms may be important in the diversification of mucosal immune responses. Selection may be exerted by local antigens, antigen-presenting cells (APCs) whose function varies in each anatomical location, cytokines, chemokines and cell-matrix interactions, thus leading to the expansion and maintenance of some clones, whereas others are diluted out or deleted. Thus, by its cellular composition, and through the compartmentalization of its afferent and efferent limbs, the MALT functions essentially independently of the systemic immune apparatus.

Although most infectious microorganisms colonize or enter the host through mucosal membranes, it is the systemic immune system which has been the focus of most vaccine research. Aside from the ease of their administration, an important advantage of mucosal vaccines is the theoretical possibility of inducing both mucosal and systemic immune responses, while the reverse does not hold true. Since specific humoral immune defense is provided by both serum and by secretory antibodies, predominately of the IgA isotype, that are selectively transported into external secretions, most vaccines considered for further improvement or development should ideally induce both systemic and mucosal responses.

Equally important to host immune defense is the capacity of MALT to promote specific immunological unresponsiveness (tolerance) after natural or deliberate mucosal exposure to a variety of antigens. This form of tolerance is considered as a major adaptive immune defense mechanism whereby we avoid developing harmful immune responses against the plethora of dietary and airborne antigens encountered each day.

Thus, from a theoretical standpoint, the possibility of manipulating the mucosal immune system towards positive immunity and/or tolerance appears extremely attractive when considering strategies aimed at protecting the host from colonization or invasion by microbial pathogens but also to prevent and/or to modulate the development of potentially harmful immunological reactions against the same pathogens and also against certain self antigens and allergens. Such considerations should finally bring mucosal vaccines to center stage in vaccine development.

Adaptive effector mechanisms in mucosal immune defense

Three major adaptive effector mechanisms participate in the immune defense of mucosal surfaces. Secretory antibody formation and antigen-specific cell-mediated cytotoxicity are the primary mechanisms involved in antimicrobial defense and act primarily but not exclusively in the epithelium of all mucosal tissues. In addition, a third form of mucosal immune defense is contributed by regulatory cells which act in both epithelium
and submucosa as well as in extramucosal tissues mainly through the production of soluble mediators. Although these cells may regulate IgA antibody formation and the development of cell-mediated cytotoxic responses, they participate in the maintenance of mucosal tolerance against most environmental matters and as such can be regarded as key players in mucosal defense against inflammation.

Secretory IgA

Immune responses expressed in mucosal tissues are typified by secretory immunoglobulin A (S-IgA) antibodies. S-IgA constitutes the predominant Ig class in human external secretions, and is the best known entity providing specific immune protection for mucosal tissues. While the synthesis and assembly of J chain-containing polymeric IgA molecules is contributed to by plasma cells, mucosal epithelial cells synthesize a secretory component which acts as a cell surface receptor to facilitate the transport of newly formed IgA across epithelial cells. The resistance of S-IgA against endogenous proteases makes antibodies of that isotype uniquely well suited to protect mucosal surfaces. S-IgA antibodies provide “immune exclusion” of bacterial and viral pathogens, bacterial toxins and other potentially harmful molecules, a function that appears to be facilitated by its affinity for binding to mucus. S-IgA has also been reported to neutralize directly a number of viruses (1,2), to mediate antibody-dependent cell-mediated cytotoxicity, and to interfere with the utilization of growth factors for bacterial pathogens in the mucosal environment.

Mucosally derived S-IgA differs from bone marrow-derived serum IgA, not only in terms of specific antibody activity but also in the proportions of polymeric vs monomeric forms (3). The ontogenies of the mucosal and systemic IgA compartments display characteristic and apparently independent patterns of maturation. Adult levels of S-IgA are reached in external secretions considerably earlier (1 month to 2 years) than in the serum (adolescence) (4, 5). Experiments that addressed the origin of mucosal antibodies have indicated that an overwhelming proportion of such antibodies are produced locally in mucosal tissues and that only a minor fraction derive from the circulation in most species, including humans (6, 7).

Mucosal cytotoxic T lymphocytes

Although the focus of most investigations has been on mucosal cytotoxic T lymphocytes (CTLs) induced by viruses, it should be borne in mind that antibody-mediated cytotoxicity and natural killer (NK)-cell activity are major responses associated with mucosal lymphocytes (8–14). The relevance of the latter responses in the field of mucosal vaccine development has not been ascertained and is therefore beyond the scope of this review.

Two major effector mechanisms associated with CTLs have been described: exocytosis from CTLs onto target cells of granules containing the pore-forming protein perforin and several serine proteases also termed granzymes, and ligation of a tumor necrosis factor (TNF) receptor-like molecule (Fas or CD95) on the target cell by FasL or TNF on the CTL side (15).

CTLs in the gut mucosa

An early study demonstrated that intraperitoneal immunization with an allogenic tumour induced specific CTLs in the gut lamina propria and epithelium at a time when very few cytotoxic lymphocytes could be detected in peripheral lymphoid organs (9).

It is now established that administration of certain enteric viruses into the gastrointestinal tract also results in early appearance of virus-specific CTLs in Peyer’s patches (16–21). Further, reovirus infection also induces effector CD8+ αβ TCR+ CTLs in the intestinal epithelium (20). Similarly, rotavirus infection induces increased pCTLs in GALT and their dissemination throughout the murine lymphoid system (17). These findings suggest that after enteric infection or immunization, antigen-induced CTLs are disseminated from Peyer’s patches via the lymphatic drainage (21), and could serve as one of the sources of pCTL progenitors destined to the epithelial defense system. The potential of this system in immune clearance of enteric viruses has been documented in several systems. Thus, mice orally infected with Toxoplasma gondii develop intraepithelial CD8+ αβ TCR+ CTLs which can transfer protection when infused into naive recipients (22). Further, effector CTLs protected against gastritis in a suckling mouse model of rotavirus infection (23). In a series of elegant studies designed to define the host determinants of rotavirus immunity, it was shown that adoptively transferred CD8+ T cells mediated clearance of rotavirus infection in severe combined immunodeficiency (SCID) mice (24–26). Although S-IgA can also neutralize rotavirus infection of epithelial enterocytes (27), these studies indicate that CD8+ CTLs are of central importance in rotavirus immunity.

Worth mentioning are the results of recent studies showing that intrarectal immunization of mice with a synthetic, multiantigen human immunodeficiency virus (HIV) peptide induced long-lasting, antigen-specific CTL memory in both the inductive (Peyer’s patch) and effector (lamina propria) mucosal sites, and protected mice against infection via mucosal challenge with a recombinant vaccinia virus expressing HIV-1 gp160 (28). These studies provide evidence for the ability of
CTLs in the airway mucosa

The kinetics of activated CTLs following virus clearance suggest that these cells do not play a very critical role in prevention of reinfection by respiratory viruses, such as respiratory syncytial virus (RSV), influenza and parainfluenza viruses. In contrast, studies in immunosuppressed animals indicate that CTLs play a central role in the resolution of established respiratory virus infections (29-31). It is likely that CTLs play also a major role in the clearance of established respiratory virus infections in humans. Studies in patients who had undergone immunosuppressive chemotherapy indicate that these patients suffer more frequent and severe infections with RSV, influenza, or parainfluenza viruses (32).

Detailed studies of immune responses after intranasal infection of rodents with influenza virus have revealed additional immune pathways involved in virus clearance. In this model, use of CD4 co-receptor knockout or other mice in whom this subset had been depleted did not affect induction of pCTLs or alter significantly clearance of infection (33). In another study, clearance of influenza was not altered by the use of β2 microglobulin knockout mice which lack CD8+ T cells or mice which had been treated with monoclonal antibody (mAb) anti-CD8 (34). In the same model, the finding that V8 T cells with several V6 chain specificities increase in the infected site as clearance occurs raises intriguing questions regarding the regulatory role of V8 T cells in antiviral immunity (35).

Several studies have also established that effector CTLs protect mice from RSV infection. The RSV F determinant, a 22 kDa glycoprotein, is a major target of pCTLs and CTL induction by RSV or recombinant vaccinia virus expressing F glycoprotein-induced protective CTLs (36, 37). In a separate line of investigation, the murine RSV model was used to determine the relative importance of CD4+ T cells, including T helper 1 (Th1) and T helper 2 (Th2)-subsets which resulted in inflammation vs immunity. These studies clearly suggest that interferon-γ (IFN-γ)-producing CD4+ Th1 cells as well as CD8+ T cells are associated with recovery, while CD4+ Th2-cells are not (38, 39). Interestingly, priming with inactivated RSV or F glycoprotein induced CD4+ Th2 cells while live RSV elicited the Th1-type pathway (38, 39).

CTLs in the genital tract mucosa

The rhesus macaque model of vaginal infection with simian immunodeficiency virus (SIV) has been useful in studies of local immunity to SIV in the female reproductive tract (40). Recent studies in this model have provided direct evidence that pCTLs occur in female macaque reproductive tissues, and that infection with SIV induces effector CTL responses in the vaginal mucosa (41). Interestingly, macaques vaginally infected with an SIV/HIV-1 chimeric virus (SHIV) displayed gag-specific CTLs in peripheral blood and resisted two challenges with virulent SIV (42).

In a recent study involving HIV-1 infected women, cervical T-cell lines established from cytobrush specimens were shown to lyse autologous targets expressing HIV-1 proteins (43). Class II MHC-restricted CD4+ CTL clones lysed targets expressing env gp41 or infected with HIV-1. Class I major histocompatibility complex (MHC)-restricted CD8+ clones recognized HIV-1 Gag or Pol-expressing targets. This study provided evidence for an MHC-restricted CTL effector function in the human female genital tract mucosa.

Regulatory T cells in the mucosal immune system

T cells are required for mucosal immunity, whether it develops as inflammation, or as tolerance or as help for specific S-IgA antibodies or CTLs in response to vaccines. B-cell commitment (μ→α switching) and B–T interactions which result in the induction of plasma cells producing polymeric IgA (pIgA) are of central importance to mucosal immunity. Cytokines and chemokines produced by CD4+ and CD8+ T-cell subsets and by classical APCs (e.g. dendritic cells (DCs, macrophages and B cells)) as well as by non-classical APCs (e.g. epithelial cells) contribute to all aspects of normal mucosal immunity, tolerance and inflammation in the immune response.

Regulatory T cells can be classified as: 1) naive, or those which have not yet encountered antigen; 2) activated (effector); and 3) memory types. Effector and memory T cells are both actively engaged in the immune response. The mucosal migration patterns of the three major subsets, along with the homing of B lymphocytes, form the cellular basis for the common mucosal immune system (44). Naïve CD4+ precursors of Th cells (pTh) normally recognize foreign peptide in association with MHC class II on APCs and express an αβ TCR*, CD4+, CD44+, CD8 phenotype. On the other hand, precursor CTLs (pCTLs) express αβ TCR which usually recognize foreign peptide in the context of MHC class I on target cells and exhibit a phenotype of CD3+, CD4+, CD8+. Thus, the MALT can be considered as a significant reservoir of pTh cells and pCTLs so that encounter with bacterial or viral pathogens can result in the induction of CD4+ Th cell and CD8+ CTL responses.

As CD4+ Th cells differentiate in response to foreign antigens, they produce distinct cytokine arrays. Naïve (pTh) cells first produce interleukin (IL)-2 and then develop into T cells
producing multiple cytokines (including both IFN-γ and IL-4), a stage often termed Th0 (45, 46). The tissue microenvironment (47), the cytokine milieu and the nature of the antigen influence the further differentiation of Th0 cells. Thus, infection with intracellular bacteria leads to the formation of Th1 cells and these cells often develop following production of IL-12 by activated macrophages (48, 49). Exogenous antigens in the mucosal microenvironment can trigger CD4+, NK1.1+ T cells to produce IL-4 for initiation of Th2-type responses (from Th0 cells) (50, 51). Th2-type cells also produce IL-4 for expansion of the Th2 subset as well as IL-5, IL-6, IL-9, IL-10, and IL-13 (52—56). This Th2 array may include production of IL-4; however, the reader should appreciate that individual cytokines are regulated through different signal transduction pathways so that not all Th1 or Th2 cells do not produce the entire array. The Th2 array of cytokines is of importance for B-cell isotype switches, and for supporting IgG1, IgG2b, IgE, and IgA responses in the mouse system (54, 57, 58).

Th1 and Th2 cells are also sensitive to cross-regulation by each other. For example, IL-12 and IFN-γ produced by Th1 cells inhibits proliferation of Th2 cells, causes an isotype switch from IgM to IgG2a (50), and inhibits isotype switching induced by IL-4 (59). Conversely, Th2 cells regulate the effects of Th1 cells by secreting IL-10 which in turn inhibits Th1 cells, from secreting cytokines such as IL-12 and IFN-γ, thus decreasing IFN-γ-mediated inhibition of Th2 cells.

While the bulk of available evidence in mice suggests that mucosal tissues favor the development of Th2-type responses, the situation is not as clear-cut in humans. Thus, freshly isolated human lamina propria T cells contain an exceptionally high frequency of IFN-γ-producing cells (60, 61) but comparatively few cells producing IL-4, IL-5 or IL-10 (61). Furthermore, even in mice, infection with recombinant Salmonella leads to the formation of Th1 cells and Th2 cells in Peyer’s patches (62). On the other hand, induction of IgA production to protein antigens is highly dependent on T helper cells (63–71). In humans, TGF-β and IL-10 in concert with IL-4 have been shown to promote B-cell differentiation into IgA-producing cells (64, 65). In this regard, it appears that in addition to resident T cells, which produce large amounts of IL-4, IL-10 and transforming growth factor (TGF)-β, human epithelial cells, also of intestinal origin, provide a major source of TGF-β and IL-10 (unpublished observations). This suggests that co-operation between neighboring lymphocytes and epithelial cells in the mucosal microenvironment is pivotal not only to promote the selective transport of newly formed IgA across epithelia but also for programing preferential maturation of IgA-committed B cells.

Finally, an additional type of CD4+ regulatory T cell has been cloned from the mesenteric lymph nodes of rodents fed repeatedly with antigens (72). These cells or “Th3” cells, produce TGF-β, variable amounts of IL-4 and IL-10, but no IL-2 or IFN-γ, and appear to exert downregulatory properties on Th1 cells (73). Since TGF-β happens to serve as switch factor for murine and human IgA, and appears to play a major role in mucosal tolerance (reviewed in (74)), these cells may have an important function in mucosal homeostasis.

**Mucosal inductive sites and generation of disseminated and compartmentalized secretory immune responses**

Generation of an immune response at mucosal surfaces, where many significant infections begin, is not readily achieved by the conventional route of parenteral injection, although this is usually effective in elicitling circulating antibodies and systemic cell-mediated immune responses. In contrast, mucosal administration of antigens may result in the concomitant expression of antibody responses in various mucosal tissues and secretions, usually without a pronounced systemic immune response (85).

Extensive studies concerning the origin of B-cell and T-lineage lymphocytes that ultimately populate mucosal tissues and secretory glands, and of immunization routes effective in the induction of secretory antibody responses, indicated that the MALT can be divided into two functionally distinct compartments; namely, inductive and effector sites. This physiological division is of paramount importance in the design of vaccines effective in the induction of protective immunity within the mucosal immune system and, in particular, its humoral branch.

Experiments performed in animal models and more recently in SCID mice engrafted with human mucosal lymphoid cells revealed that the inductive sites present in certain locations, such as Peyer’s patches in the small intestine, or in some species the tonsils in the upper aerodigestive tract, function as primary sources of precursor cells that migrate through the lymphatics and blood, and after directed extravasation populate remote mucosal tissues and glands (75–78). These studies have led to the notion of a common mucosal immune system (Fig. 1).

It is generally believed that antigens taken up by specialized epithelial cells (“M” cells or “membranous cells”) covering mucosal inductive sites can be channeled to parenchymal macrophages, DCs, B lymphocytes, and even mast cells, and/or they can be processed and perhaps presented directly by epithelial cells to underlying B and T cells. Following interaction of the antigen with accessory cells and cognate helper T cells
and/or B lymphocytes in the local lymphoid microenvironment, an immune response may ensue. With the majority of antigens this results presumably in suppression of specific immunity – “mucosal tolerance” (see below). However, development of an active immune response may also follow mucosal intake of antigen, and the characteristics of the immune response generated, including the balance between active immunity and suppression/tolerance may be influenced by several factors, including the nature of the antigen, the type of accessory cells, cytokines and lymphocytes involved, and the genetic background of the host. Two major types of active immune responses may develop either concomitantly or separately: antibody formation (mainly SIgA) and cell-mediated immunity. The sensitized immunocytes, in particular antigen-sensitized B cells but presumably also T cells, leave the site of initial encounter with antigen, e.g. a Peyer’s patch, transit through the thoracic duct, enter the circulation and then seed both that same mucosa and other distant yet privileged mucosal sites. In their new locations, the committed B cells may further differentiate into plasma cells producing antibodies, mainly dimeric IgA, under the influence of locally produced cytokines.

This IgA cell cycle was first elucidated in animals through the adoptive transfer of cells from the gut- and bronchus-associated lymphoid tissues (GALT and BALT) into recipients whose mucosal tissues and glands were populated by IgA plasma cells of donor origin. Most importantly for vaccine development, evidence for the existence of a common mucosal immune system in humans has been strengthened in recent years by several studies. In addition to the detection of specific S-IgA antibodies in remote secretions induced by natural exposure to antigens or oral immunization, analyses of IgA-secreting cells from peripheral blood and mucosal tissues after enteric immunization provided strong support for this concept (79–81). Differential utilization of organ-specific endothelial cell recognition mechanisms by circulating IgA immunoblasts induced after mucosal vaccination has also been demonstrated in humans (82, 83). Taken together with studies in the murine
Gut-Associated Lymphoid Tissues (GALT)

system, this finding may explain both the unification of humoral immune responses in diverse mucosal sites and the physiologic segregation of mucosal from non-mucosal immune mechanisms.

Based on the concept of a common mucosal immune system through which a fraction of lymphocytes activated in the gut, e.g. by ingestion of antigen, can disseminate immunity not only in the intestine but also to other mucosal and glandular tissues, there is currently much interest in the possibility of developing oral vaccines against both enteric and non-enteric mucosal infections, e.g. in the respiratory or genital tract. However, recent studies involving immunizations of human and non-human primates as well as rodents with prototype non-replicating immunogens, such as cholera toxoids or cholera toxin indicate that a substantial degree of subcompartmentalization exists within the mucosal immune system, and even within a given mucosal organ such as the gut, regarding both homing of IgA plasma cell precursors and final redistribution of their progenitors.

The MALT is comprised of anatomically defined lymphoid microcompartments, such as the Peyer’s patches in the small intestine, the appendix and solitary follicles in the large intestine and in the rectum, the nasal mucosa and the tonsils at the entrance of the aerodigestive tract, which serve as the principal mucosal inductive sites where immune responses are being initiated (84–87). It also contains diffuse accumulations of large numbers of lymphoid cells that do not associate into apparently organized structures. These cells are either distributed in the lamina propria or interspersed among epithelial cells in mucosal tissues and glands, and form the mucosal effector sites where immune responses are being expressed. The gut mucosa is particularly well invested with such diffuse lymphoid tissues.

More important for vaccine development is the fact that immunization at certain inductive sites may give rise to a humoral immune response preferentially manifested at certain effector sites. Thus, a given inductive site may serve as a preferential but not exclusive source of precursor cells for certain mucosal tissues.
Inductive sites in the gut-associated lymphoid tissues (GALT)

The gut contains the most abundant lymphoid tissues and includes organized as well as diffuse lymphoid elements. Organized lymphoid tissues are comprised of two units – B-cell follicles and para- or interfollicular T-cell areas – assembled within a matrix of loose connective tissue and follicular DCs. These follicles occur singly or in groups and harbour variable numbers of macrophages and T cells (88).

Follicle-dome structures form the main lymphoid component of the Peyer’s patches in the jejunum and ileum and are also found in the large intestine, and especially in the appendix. These structures appear to play an important role in the induction of disseminated immune responses to oral vaccines (Fig. 2). Typically, the follicles contain a majority of B cells, approximately half of which are activated. The T-cell zone comprises a majority of CD4+ T cells; CD8+ αβ TCR T cells are mainly located in the parafollicular area whereas CD8+ γδ TCR T cells are rare. The dome is covered by a specialized epithelium or “follicle-associated epithelium” (FAE), containing antigen-transporting M cells.

The cecal and colonic mucosae are also variably invested with comparable lymphoid patches, although the epithelium covering these lymphoid aggregates does not show the specializations of M-cell-containing FAEs (89, 90).

Clusters of follicles are also found adjacent to the ano-rectal junction (91, 92). The potential importance of the rectal lymphoid tissues as an IgA inductive site and as a source of IgA plasma cell precursors is suggested by several studies. First, the predominance of IgA2 cells over IgA1 cells in the lamina propria of the large intestine clearly diverges from the relative apportioning of the two in other mucosal tissues, such as in the small intestine and in the upper large intestine (93). Further, rectal immunization of humans, non-human primates and rodents has been shown to induce strong secretory antibody responses in the rectal mucosa. Although in most instances, rectal immunization induced secretory antibody responses in the rectal mucosa itself (94–100), in some instances, rectal vaccination could induce specific antibodies in serum, and also in secretions from remote mucosal organs, such as saliva (102), and genital secretions (92–94, 96). Although the potential of the rectal mucosa to serve as site of induction of mucosal responses is now well established, it should be pointed out that rectal immunization of macaques with CT, one of the most powerful mucosal immunogens, was shown to be poorly effective at inducing an immune response in the upper part of the intestine and especially in the small intestine (100).

Recently, a new type of “organized” lymphoid tissue, termed the cryptopatch, has been identified in the murine intestine (101). These consist of microscopic aggregates (a few hundred cells) of immature lymphocytes clustered in the lamina propria. Although cryptopatches have not yet been identified in humans, it has been proposed that they represent a precursor source of intestinal intraepithelial T cells. The potential role of these structures in the induction of active immunity or tolerance to mucosally encountered antigens remains to be explored.

Inductive sites in the naso-pharyngeal lympho-reticular tissues (NALT)

Several recent studies have emphasized the importance of the nasal cavity for the generation of mucosal and systemic immune responses that may exceed in magnitude those induced by oral immunization (83, 102–111). When introduced into the nasal cavity, usually along with mucosal adjuvants, viral and bacterial antigens induce superior immune responses in external secretions such as saliva and, surprisingly, in female genital tract secretions. Because neither IgG nor IgA antibody titers in vaginal washes correlate with serum antibody responses, it is assumed that antibodies of both isotypes are predominantly of mucosal origin. This finding may have important implications for the design of vaccines effective in the induction of immune responses in the genital tract.

Thus, different immunization routes (intranasal and oral) can induce generalized mucosal immune responses, although the relative representation of dominant antibody isotypes may vary. Nevertheless, nasal immunization appears to induce S-IgA immunity in a broader range of mucosal tissues than oral vaccination. This may be explained by the recent observation that circulating IgA-secreting cells induced after nasal vaccination express a more promiscuous profile of homing receptors than their corresponding counterparts raised after oral or rectal immunization (82, 83). Whether such antibody responses are also induced in the male genital tract remains to be determined.

Immunohistochemical studies have indicated that the epithelium of the human nasal mucosa contains intraepithelial lymphocytes (IELs) staining predominantly for CD3, CD2, CD8, and CD5, but lacking Leu8 (homing receptor analogue of Mel14) (123, 124). Few (<10%) nasal IELs stain for CD4. Nasal IELs rarely express HML1, whereas the majority of intestinal, tonsillar and adenoidal IELs are HML1+. HLA-DR+ intraepithelial DCs have also been identified in nasal mucosa specimens. Virtually no B cells and no organized subepithelial lymphoid tissue are found in the normal human nasal mucosa. In contrast, the nasal mucosa of adult rats and mice comprise lymphoid structures with distinct T- and B-cell areas (112, 113). Furthermore, the majority of intraepithelial lymphocytes...
phocytes populating the nasal epithelium are slg+ B cells with a few CD4+ or CD8+ T cells in rats (112), whereas the murine nasal epithelium is infiltrated mainly with CD4+ T lymphocytes with very few B cells (113). Thus, the human nasal mucosa seems to differ from that of rodents—the most commonly used animals in preclinical vaccine studies—and also from endodermically derived human mucosae, such as the tonsils and adenoids. The latter lymphoid structures appear to be the major sites of induction of mucosal immune responses to inhaled antigens in humans.

Strategically positioned at the entry of the aerodigestive tract, the palatine, lingual and nasopharyngeal tonsils (Waldeneyer’s ring) are continuously exposed to ingested and inhaled antigens. These glands possess structural features resembling both lymph nodes and Peyer’s patches (87), including a lymphoepithelium which contains M cells in tonsillar crypts, and which are essential for antigen uptake (Fig. 2). In addition, germinal centers containing B and T cells, plasma cells, and professional APCs are also present. Several observations have suggested that these lymphoid tissues may serve as a source of precursors of IgA plasma cells found in the upper aerodigestive tracts: the distribution of IgA1- and IgA2-producing cells in the nasal and gastric mucosae and in lacrimal and salivary glands is similar to that found in tonsils. Furthermore, the S-IgA immune response to oral poliovirus vaccine is reduced in tonsillectomized children compared to children with intact tonsils (114). Direct unilateral injection of antigens into the tonsil of human volunteers resulted in the induction of local immune responses manifested by the appearance of antigen-specific IgG-producing and to a lesser degree IgA-producing cells in the injected tonsil (103). Furthermore, considerable numbers of antibody-forming cells with a similar distribution of isotypes were detected in peripheral blood, suggesting that the tonsils may serve as an inductive site, analogous to Peyer’s patches, that is effective in the stimulation of generalized mucosal immune responses.

Inductive sites in the genital tract mucosa

Although long considered as immunologically incapable of supporting an active immune response against locally encountered antigens, but especially against spermatozoa or preimplantation embryo, the female reproductive tract mucosa has been shown to comprise all cell populations required for initiating an immune response. HLA-DR+ Langerhans cells have been identified in the vaginal and cervical epithelia (117, 118), being most abundant in the vulval epithelium. Intraepithelial T cells have been identified at all sites and comprise a majority of CD8+ cells, the latter being particularly abundant in the transformation zone (117). A significant proportion of these cells express perforin and TIA-1 (119), suggestive of cytolytic capacity. In contrast, CD4+ T cells are rarely found in these epithelia but predominate in the submucosa of the vagina, cervix and fallopian tubes. The submucosa of the vagina, cervix and fallopian tubes contains large numbers of J-chain- and IgA1- and IgA2-containing plasma cells, and the epithelium of the fallopian tubes and cervix stains for secretory component and has thus the potential to transport polymeric IgA (120, 121).

Vaginal immunization of human and non-human primates with cholera toxoid and CT, respectively, has been shown to evoke serum antibody responses and secretory IgA and IgG responses in cervico-vaginal washes (100, 122, 123). Further, in female macaques immunized with CT applied into the vagina, these responses were associated with large numbers of IgG and IgA antibody-secreting cells (ASCs) in the cervical and vaginal mucosae (100), demonstrating active production of such antibodies at local sites. However, this route of immunization was poorly if at all effective in inducing an IgA immune responses in other mucosal compartments (100).

Although all components of the mucosal immune system are present in the female reproductive tract, the precise sites of induction of secretory immune responses in this organ are largely unknown. The most likely scenario involves antigen uptake by intraepithelial Langerhans cells which then migrate to draining lymphoid tissues where they actively educate naive T and B cells. These in turn migrate via the efferent lymph and the blood circulation and seed to the submucosa where they differentiate into effector cells. Draining iliac lymph nodes appear to be the most likely site of initiation of such responses (92).

Thus, within the context of the common mucosal immune system, certain organs may favor the development of IgA-committed precursors B cells whose progeny is preferentially destined to particular mucosal locations. This new knowledge should call for more site-directed vaccination strategies.

Mucosal anti-infectious vaccines

Since Jenner introduced vaccination over 200 years ago, fewer than 50 vaccines have been approved for human use, nearly half of which are improved versions of earlier forms. All but five of the current vaccines—the oral poliovaccine, the oral killed whole cell/B subunit cholera vaccine, the oral Salmonella typhi vaccine, an oral rotavirus vaccine and nasal live-attenuated influenza virus vaccines which have completed phase III clinical testing—are administered parenterally and as such do not provide significant mucosal immunity.
It is now almost axiomatic that in order to be efficacious, vaccines against mucosal infections must stimulate the MALT, and that this goal is usually better achieved by administering immunogens by a mucosal route rather than parenterally. However, even so, stimulation of secretory immune responses by mucosal administration of non-replicating antigens is often relatively inefficient, requiring multiple administrations of large quantities of immunogens and yielding most often tolerance and, if at all, modest immune responses. This conclusion is physiologically justifiable since the primary function of the mucosal immune system is to prevent the overstimulation of the entire immune system. It does so by eliminating mucosally applied antigens with denaturing acids, degradative enzymes and other innate factors as well as through intestinal peristalsis and ciliary movement on epithelia in the respiratory tract.

Against this background, mucosal vaccinologists have elaborated numerous delivery systems and adjuvants which partly circumvent such natural obstacles. The ever-growing list of mucosal delivery systems described in the literature bears witness to the difficulties encountered and to the limited practical usefulness of most delivery devices. We will therefore concentrate on the most promising systems. Furthermore, it should be emphasized that most of the results have been obtained in animal models rather than in humans with all unavoidable limitations.

Inert vaccine delivery systems

Because antigens are more immunogenic in particulate form than in solutions, and because they are vulnerable to antigen-degrading enzymes and acids, they have often been incorporated into vehicles that are by themselves non-toxic and non-immunogenic, and which protect vaccine material from degradation, enhance their uptake from mucosal surfaces, and may exhibit an adjuvant effect. Gelatin capsules coated with substances (e.g. cellulose acetate phthalate) that dissolve at alkaline pH in the intestine but not at acid pH in the stomach have been used for oral delivery of bacterial and viral vaccines in several studies performed in humans but their usefulness has never been systematically assessed (125-127).

To avoid the fast passage of free antigens, mucoadhesive polymers that adhere to mucosal surfaces and thus extend the time of exposure of vaccines have been used in several recent studies (123, 128, 129). When compounds such as highly viscous polysaccharide edexomer (123) and carboxymethyl cellulose (128) are used with an antigen such as influenza virus or CT-B that has been orally, intranasally, or intravaginally administered, both local mucosal and systemic immune responses are induced. Other compounds that have been considered are carbopol, polycarbophil, sodium alginate, and hydroxypropyl cellulose, which are used in medicine for drug delivery.

Liposomes have been used for mucosal vaccination in a few studies, while bacterial or viral antigens have been administered orally or intranasally to rodents, monkeys and humans, resulting in the induction of mucosal and systemic immune responses (reviewed in (130)). A related antigen delivery system, cochleates, composed of protein–phospholipid–calcium precipitates with entrapped antigens, has been used for mucosal delivery of glycoproteins or peptides from influenza virus and SIV (131). As with liposomes, humoral as well as cell-mediated immunity (CMI) have been induced when given by the oral route.

Biodegradable microspheres composed of antigens incorporated into polymers of lactic and glycolic acid have been used far more extensively in mucosal vaccinology than any other inert delivery system (132-135). Microspheres have gained popularity because of their stability which allows them to protect incorporated antigens from acids and enzymes, and because of the ease with which their size and rate of biodegradation can be modified. Further, microspheres are by themselves non-antigenic and so can be easily reused, offering an advantage over live vectors. The rate of release of antigens can theoretically be controlled by mixing fast- and slow-releasing microspheres, allowing for the induction of combined primary and secondary immune responses by a single immunization (132). Finally, it would seem possible to incorporate immunoregulatory cytokines or DNA encoding for different antigens to achieve a desired immune response, and attempts to do so are in progress.

These obvious attractive features of the inert delivery systems are counterbalanced by serious disadvantages. Specifically, the disappointingly low absorption rate, usually much less than 1% of the ingested dose, renders the procedure expensive. Moreover, the use of organic solvents during the incorporation of antigens may severely compromise the immunogenicity of such vaccines. However, attempts are being made to increase the absorption rate and to develop conditions of incorporation that minimize degradation of antigens.

Mucosal lectin-like molecules as carrier-delivery systems

Oral administration of small amounts of protein antigens covalently coupled to carrier molecules with known affinity for mucosal epithelial cells, such as CT, Escherichia coli heat-labile toxin (LT), CT-B and LT-B, can elicit mucosal and also, under certain conditions, systemic antibody responses to the conju-
gated antigen (136–138). This strategy has also recently been utilized to induce mucosal immune responses to carbohydrate antigens (139).

Fusion proteins created from hybrids of CT-B or LT-B with genes encoding heterologous antigens have also been generated (140, 141), and are preferable to chemically coupled proteins in that they are free of contaminating holotoxin and are uniform in structure. Overexpression systems have also been developed to facilitate large-scale production of such fusion proteins (142). Others have created fusions between antigens and CT-B-CT-A2 mutants which lack the toxic A1 subunit (143–145). Interestingly, though oral administration induced serum IgG antibodies, maximum mucosal IgA responses required addition of the whole CT. Thus, it appears that CT-B is an excellent carrier molecule due to its ability to bind to GM1 receptors on epithelial cells but at best exhibit low adjuvant properties.

Live recombinant microorganisms as mucosal delivery systems

It has long been assumed that only live vaccines would efficiently stimulate a mucosal immune response since the majority of microbial pathogens colonize or enter through mucosal surfaces and hence have evolved strategies to circumvent natural physico-chemical barriers. Furthermore natural infection with a number of microbial pathogens induce strong immune responses in both mucosal and systemic compartments and these responses are often protective against reinfection. The use of live attenuated recombinant bacteria and viruses, which can be genetically engineered to synthesize unrelated antigens, has the obvious advantage that it is theoretically possible to package the same recombinant organism with genes encoding several unrelated antigens. Recombinant bacterial and viral vectors which contain genes from unrelated pathogens that encode important virulence factors have been explored in many experimental vaccine studies (146). The development of recombinant vectors has been facilitated by rapid progresses relating to complementary DNA cloning of large DNA inserts and the advancement of polymerase chain reaction-based techniques. The ability of a vector to colonize specific mucosal locales and to generate an immune response at desired sites is an important factor in determining its suitability as vaccine vehicle. The most important factor to be considered is the ability of a given vector to induce certain types of immune responses. Experience so far indicates that in general, mucosal administration of recombinant bacteria or viruses may induce mucosal S-IgA responses, and in most instances these responses are associated with priming of Th1-type helper responses which may not always be desirable. Although many bacterial and viral vectors have been used in animal models (147), only recombinant Salmonella, adenoviruses and poxviruses have been used with limited success in humans.

Salmonella presented by the oral route replicates in Peyer’s patches and disseminates via the mesenteric lymph nodes to systemic sites, such as the spleen. This characteristic pattern of migration allows Salmonella to induce a broad-based immune response which includes cell-mediated as well as serum and mucosal antibody responses. Attenuated avirulent Salmonella strains have therefore received particular attention as mucosal vaccine delivery vectors for recombinant proteins associated with virulence (148–153). Although a large number of genes from bacteria, viruses, and parasites have been expressed in attenuated Salmonella, a critical balance between attenuation, adequate expression and immunogenicity has often been difficult to achieve.

Only recently have studies begun to characterize both mucosal T- and B-cell responses to recombinant antigens expressed in Salmonella, particularly in terms of the balance between antigen-specific CD4+ Th1 and Th2 cells and their influence on the types of ensuing immune responses. Mice given an oral attenuated Salmonella vaccine displayed CD4+ Th cells which produced IFN-γ and IL-2, but not IL-4 (154), immediately raising the question of as to how such T-cell help is also provided for mucosal S-IgA antibody responses. Oral delivery of rSalmonella which express the Tox C gene of tetanus toxoid (TT) resulted in predominant serum IgG2a and mucosal S-IgA antibody responses (62, 155). Splenic and Peyer’s patch T cells selectively produced IFN-γ and IL-2 as well as the Th2-type cytokine IL-10. IL-4 was shown not to be involved in anti-Salmonella and anti-TT IgA responses by experiments in IL-4 knockout mice. Interestingly, CD4+ Th cells in these IL-4 knockout mice exhibited two distinct cytokine patterns: a Th1-phenotype of IFN-γ and IL-2, as well as T cells which produced IL-6 and IL-10, but no IL-5 (155).

Intranasal immunization has emerged as perhaps the most effective route for induction of both peripheral and mucosal immunity to vaccines. The usefulness of Mycobacterium bovis strain Bacille Calmette Guérin (BCG) as a delivery system for recombinant antigens has been documented in several models. Specifically, BCG-vectored outer surface protein and pneumococcal protein A conferred protection against Bordetella and S. pneumoniae, respectively, when given nasally to mice (reviewed in (156)). Recently, attenuated Bordetella pertussis strains have been constructed by deleting the pertussis toxin gene and have been used as live vectors for intranasal delivery of heterologous antigens expressed at the surface of B. pertussis via fusion to the filamentous hemagglutinin (FHA) gene (157). Intranasal delivery
of B. pertussis expressing a parasite antigen fused to FHA induced strong mucosal immune response but relatively modest serum antibody responses to the fused antigen. Nevertheless, such an approach could be used for the construction of combined vaccines to protect not only against whooping cough but also against other respiratory infections.

Adenoviruses (r-Ad) have proven to be rather attractive systems for tissue targeted delivery of mammalian and microbial genes in gene therapy and in vaccinology, respectively. However, in both instances host immune responses develop to r-Ad and precludes readministration of the vector (158, 159). Despite these drawbacks, the use of r-Ad remains a promising approach in both arenas. Most studies to date have been performed with r-Ad from which the E1 and E3 genes have been deleted, rendering virus replication deficient. A major advantage of the current generation of r-Ad vectors is their capacity to accommodate large amounts of exogenous cDNA (7–8 kilobases), a feature which has been used to express virulence genes from a number of viral pathogens. However, the virions retain full competence for infection of mucosal epithelial cells in the respiratory tract (159, 160). In recent studies, r-Ad expressing herpes simplex virus glycoprotein B was shown to be a most effective vaccine when given by the intranasal route to mice (104, 105, 161). This regimen induced serum IgG as well as pulmonary IgA anti-glycoprotein B responses which correlated with protection from challenge. Further, this vaccine induced an effective CTL response (162). The same authors have also demonstrated that this vector induced specific secretory immune responses in the rodent female genital tract (104). This mucosal route of immunization also appears to be safe and effective, since intranasal, intratracheal and oral delivery of SIVenv glycoprotein by an r-Ad to macaques (163) and intranasal immunization of chimpanzees with a r-Ad expressing HIV envelope and gag genes (102) resulted in significant serum antibody responses. These antibody responses were broad-based, and when boosted with a gp160 subunit vaccine, elicited serum neutralizing antibodies. Recombinant Ad have also been used as vector for rabies virus in order to orally vaccinate foxes (164). In addition, oral administration of r-Ad expressing RSV and hepatitis B virus sequences have successfully induced circulating antibody responses in dogs and chimpanzees (165, 166). Moreover, intranasal or enteric immunization with a r-Ad expressing bovine coronavirus hemagglutinin-esterase glycoprotein induced virus specific mucosal immune responses in cotton rats (167). Despite these significant advances, further studies will obviously be required to determine optimal mucosal immunization protocols and to enhance the expression of desired antigens while diminishing responses to the vector to allow for vaccine readministration. In this respect, a recent study indicates that induction of mucosal tolerance (see below) to the r-Ad vector can be accomplished by prior mucosal exposure to inactivated adenoviral vector (168).

Recombinant poxviruses have been used in numerous studies including human clinical trials when given by systemic routes (by scarification, subcutaneously or intramuscularly), but studies documenting their mucosal immunogenicity are still limited. This is somewhat surprising given the effectiveness in wild animals of an oral vaccine against rabies (169) based on a recombinant vaccinia virus expressing the rabies glycoprotein gene (170). Oral administration of recombinant vaccinia virus encoding influenza virus hemagglutinin and neuraminidase induced both systemic and secretory anti-influenza antibody responses in mice (171, 172). Although relatively straightforward to generate in high yields and to purify, replication-competent recombinant vaccinia viruses pose potential problems for being used as mucosal vectors, including the risk of widespread infection in immunocompromised individuals. Vector systems based on avian poxviruses (fowlpox or canarypox-ALVAC) or an attenuated vaccinia virus (NYVAC), have now been developed which allow only single round infections in mammalian cells (173). Intranasal immunization of ferrets with NYVAC and ALVAC vectors expressing canine distemper virus HA and F genes were equally potent in protecting these animals against CDV challenge; intraduodenal administration was only partly effective (174). Parallel evaluation of different vector systems is rarely found in the literature. In one study, the efficacy of r-Ad and NYVAC vectors expressing pseudorabies gD glycoprotein was compared after intranasal and intramuscular immunization. They have demonstrated that, while the adenovirus proved more efficient than the poxvirus vector to elicit an antibody response, the survival times of animals after challenge with pseudorabies virus was comparable (175). More recently, the modified vaccinia Ankara (MVA) strain of vaccinia virus has attracted the interest of many investigators. Indeed, MVA is a highly attenuated non-propagative strain of vaccinia which has been obtained after more than 500 consecutive passages in chicken embryo fibroblasts (176). The immunogenicity of recombinant MVA-based vectors by the parenteral route has recently been demonstrated (177) and MVA holds promises as a safe and effective mucosal vaccine delivery system. More generally, such non-replicative poxviral vectors are promising mucosal delivery systems.

The use of RNA viruses as vectors initially lagged behind the use of DNA viruses, mainly due to the relative ease of manipulating DNA genomes. Given the progress in recombinant DNA technology, the development of RNA viruses as vac-
cine vectors has now caught up with DNA viruses (reviewed in (178)). Recombinant vaccine strategies using RNA viruses such as poliovirus, alphaviruses (Venezuelan equine encephalitis virus (VEE), Semliki Forest virus), and paramyxoviruses (RSV) as vectors are being actively explored for mucosal immunization. In particular, replication-competent VEE expressing HIV p18 and p24 gag (179) or influenza virus HA genes (180) have been shown to induce mucosal and cellular immune responses. Interestingly, a replicon vaccine vector system was developed from an attenuated strain of VEE (181). The replicon RNA consists of the cis-acting 5' and 3' ends of the VEE genome, the complete non-structural protein gene region, and the subgenomic 26S promoter. Immunization of mice with the VEE replicon expressing the influenza HA or Lassa virus N gene induced antibody responses against the expressed protein and demonstrated a capability for sequential immunization to multiple pathogens in the same host (181). Likewise, recombinant poliovirus can be engineered as replication-competent vector (182) or as replicon (183) (reviewed in (178)). The unique aspects of these viruses, including their port of entry, point to promising developments in mucosal vaccinology.

Mucosal DNA vaccines

Since Wolff and colleagues (184) reported that direct intramuscular injection of mice with plasmid DNA encoding the complete sequence of a gene resulted in durable expression of the encoded protein, immunization with plasmid DNA encoding virulence genes of several important pathogens has been shown to induce protective immunity in several preclinical studies (185). Although many issues, including safety considerations, will need to be carefully assessed, this approach offers substantial advantages. Aside from stability and ease of production, these include the induction of immunity by a non-infectious agent, and thus the possibility of vaccinating against organisms with a propensity for long-term persistence in the body, e.g. cytomegalovirus and HIV. Furthermore, DNA immunization would allow the selection of nucleic acids corresponding to a broad range of polypeptides to overcome the problem of MHC genetic restriction in outbred populations. In addition, the plasmid backbone can also be equipped to harbour sequences encoding cytokine genes so as to facilitate the type of immune response desired.

In principle, the DNA used for vaccination is a plasmid containing a bacterial origin of replication and an antibiotic resistance gene, required for selective plasmid production in E. coli. The gene of interest is cloned under the control of a strong promoter (usually a viral promoter). In addition to the expression cassette, the plasmid may contain immunostimulatory sequences which appear to be critical in governing the immunogenicity of the expressed gene. These sequences include a non-methylated CpG motif within a palindromic hexamer oligonucleotide sequence (186, 187) and have been reported to induce B-cell proliferation (188) and Th1 cytokine production (189, 190). The stimulatory properties of such motifs appears to be mediated via the selective activation of DCs (191). It is interesting to note that mucosal administration of synthetic oligodeoxynucleotides containing CpG motifs enhances virus specific responses, suggesting that such nucleotides could be used also as mucosal adjuvant (192).

Although the majority of studies so far have dealt with intramuscular and intradermal administration of DNA vaccines, this approach has gained popularity among mucosal vaccinologists. Naked plasmid DNA can be directly used for mucosal immunization (193–197). Thus, intranasal or intratracheal administration of a DNA plasmid encoding influenza virus hemagglutinin induced protection against a lethal influenza virus challenge in mice (185). More recently, intranasal immunization of mice with a DNA plasmid encoding lacZ and herpes simplex virus type 1 glycoprotein B (gB) induced lacZ and gB expression in lungs and cervical lymph nodes (195). Although a distal mucosal IgA response and an anti-HSV cell-mediated immune response were observed following three i.n. administrations of gB DNA, protection against lethal vaginal HSV challenge was lower than that seen after intramuscular administration of the same plasmid. Intrabuccal injection or nasal administration of plasmid DNA encoding measles virus hemagglutinin induced systemic MHC class I-restricted CTL responses (196). Further, intravaginal instillation of a plasmid DNA encoding the HIV-1 envelope glycoprotein elicits production of IgA and IgG antibodies in vaginal fluids and serum neutralizing antibodies (194). The same construct was employed to demonstrate that plasmid DNA vaccination of infant chimpanzees was well tolerated and could induce serum antibodies to HIV-1 (197).

As for conventional vaccines, several formulations have been developed to facilitate the uptake of plasmid DNA-based vaccines and to protect them from degradation in the mucosal microenvironment. The use of liposomes, cationic lipids, monophosphoryl lipid A for mucosal delivery of DNA (198–201) has been shown to increase both expression and immunogenicity of the corresponding protein, suggesting that the lipid matrix may also provide a secondary role as adjuvant by facilitating DNA uptake by APCs or by promoting local inflammation. In the case of oral delivery, plasmid DNA can also be protected from degradation in the gut by encapsulation
in poly(DL-lactide-co-glycolide) (PGL) microparticles (202, 203).

Attenuated intracellular bacteria such as Salmonella, which are retained within vacuoles in the infected cell, have recently shown promise for the delivery of plasmid DNA. Thus, infection of peritoneal macrophages with S. typhi carrying a plasmid encoding lac Z results in the transfer of plasmid DNA into the infected cell (204). Very recently, this approach has been employed to demonstrate that oral administration of S. typhi carrying a tumor antigen results in gene transfer in host DCs and protects mice against fibrosarcoma (205).

The mechanisms underlying the induction of an immune response after mucosal DNA vaccination are still unknown, but are likely to be analogous to those involved after systemic (intramuscular, intradermal) DNA administration (206–209): transfer of antigen from tissue-transfected epithelial cells to professional mucosal APCs (cross-priming), or direct transfection of professional APCs and especially DCs.

Edible vaccines
Mucosal vaccines would be more widely used – especially in developing countries – if they could be produced at lower cost, and distributed without refrigeration. The concept of vaccine production in transgenic plants was introduced recently (210), and was based on the premise that plants have the capacity to produce abundant biomass, and that recombinant immunogens could be produced in plant tissues. Since plants can be engineered to contain multiple foreign genes, multicomponent transgenic plant vaccines should therefore be feasible. Several plant expression systems, e.g. potato and tobacco plants, have been developed and shown to allow expression of microbial antigens such as hepatitis B surface antigen, E. coli LT-B, and even Norwalk Virus-like particles (VLPs) (reviewed in (211)).

Although the levels of expression of recombinant antigens have so far been very disappointing, feeding animals with potato tubers expressing Norwalk VLPs or E. coli LT-B induced specific secretory IgA antibody responses and serum IgG responses to the transgenic protein (211). Developing strategies to increase antigen expression in edible plants, including the use of strong tissue-specific promoters remain one important challenge in this area of vaccine development.

Dendritic cells as vaccines against mucosal infections
DCs are potent APCs that play a central role in the induction of immunity as initiators and immunomodulators of immune responses (212). Owing to their capacity to prime T cells, DCs loaded ex vivo with tumor antigens have been extensively used as potential cancer vaccines (213, 214). Given promising pre-clinical results, studies are now underway in patients. That adoptive transfer of DCs pulsed ex vivo with infectious microorganisms could constitute a way to induce broad-based immunity against infectious diseases has also been documented (215–217).

To date, the potential of DCs as vaccine carriers for the induction of mucosal responses is largely unknown. In this respect, a recent study has shown that DCs pulsed ex vivo with killed chlamydiae and subsequently transferred into naive recipients were able to induce protective CD4+ Th1 immune responses against genital challenge with chlamydia (218). Although this study used bone marrow-derived DCs, it is the first one to document the efficacy of this approach against a mucosal infection.

Bacterial enterotoxins as mucosal adjuvants

The introduction of proteins including vaccines into mucosal inductive sites is an effective way to induce systemic unresponsiveness (mucosal tolerance). Thus, mucosal adjuvants are required not only to boost mucosal and systemic immunity, but also to prevent the induction of mucosal tolerance.

Although a variety of compounds have been reported to display adjuvant properties on mucosally co-administered antigens, the most powerful and hence most studied mucosal adjuvants are the Vibrio cholerae exotoxin CT, and its structural and biological analog LT. These macromolecules are composed of two structurally, functionally and immunologically separate A and B subunits (219). The B subunit of both toxins consists of five identical monomers, but the pentameric B subunit of CT (CT-B) binds only to GM1 ganglioside, while the B subunit pentamer of LT (LT-B) is more promiscuous and binds to GM1 as well as to asialo GM1, GM2, and glycoprotein receptors (220). After the B subunit binds to epithelial cell GM1 or GM2 receptors, the A subunit reaches the cytosol and binds to NAD to catalyze ADP-ribosylation of Gsa. This GTP-binding protein activates adenyl cyclase with subsequent elevation of cAMP, which in epithelial cells results in secretion of water and chloride ions into the small intestine.

Mucosal exposure to CT and LT, which are both immunogenic, results in S-IgA and serum IgG antibodies, which are almost entirely restricted to CT-B or LT-B. More importantly, both toxins are potent mucosal adjuvants for unrelated proteins co-administered by oral, intranasal or even parenteral routes (221–223).

Recent studies suggest that oral or nasal immunization with proteins along with CT as adjuvant induces Th2-type responses in the intestinal mucosa (224–226). Such an immu-
nization protocol induced CD4+ Th2 cells in Peyer’s patches and
the spleen (224) as well as high IgG1 and IgE responses, in the
absence of detectable IgG2a titers (226, 227). Further, oral
immunization with keyhole limpet hemocyanin (KLH) and CT
mixed with CT-B resulted in Peyer’s patch and lamina propria
T-lymphocyte populations which produced low IL-2 and IFN-
γ but high levels of IL-4 and IL-5 (228).

However, other studies have shown that oral co-administra-
tion of a soluble or particulate antigen and CT primed ani-
mal for systemic Th1-type immune responses (delayed-type
hypersensitivity) (229) and induced functional CTLs in the
spleen (230). Again, the results from these studies suggest that
oral immunization with heterologous antigen and CT as an
adjuvant can differentially affect mucosal and systemic immune
responses, inducing Th2-type immune responses in mucosal
tissues and Th2 as well as Th1-type responses in the systemic
compartment. Thus, not only the nature of the adjuvant, but
also that of the antigen used, and the mucosal route of delivery
can all influence whether Th1- and/or Th2-type responses
develop.

CT and LT cause severe diarrhea in humans and account for
the clinical manifestations of cholera and enterotoxigenic E. coli
enteritis, and thus neither is suitable for use as an enteric adju-
vant in humans. Early studies attempted but failed to dissociate
diarrhoeagenicity from the adjuvanticity of these two mole-
cules. For example, a non-toxic mutant, formed by making a
single amino acid substitution in the ADP ribosyltransferase
active center also lacked adjuvanticity when administered orally
(231). However, mutants of LT formed by substituting a single
amino acid either in or outside the ADP-ribosyltransferase cleft,
retained adjuvanticity despite apparent lack of toxicity when
administered by the intranasal route (108, 232–234). More-
over, two mutants of CT, which harbor single amino acid sub-
stitutions in the ADP-ribosyltransferase active center and com-
pletely lack ADP-ribosyltransferase activity and diarrhoeagenic-
ity, remained effective adjuvants and were comparable to native
CT when given parenterally or nasally (235, 236). We have
ourselves found that recombinant CT-B and LT-B are also moder-
ately adjuvant when co-administered with other protein anti-
gens by the nasal route but not by the oral route (C. Czerkinsky,
J. Holmgren, unpublished observations). Since enterotoxity is
the main obstacle to the use of native CT or LT as oral adjuvants,
it will be interesting to determine whether enzymatically inac-
tive CT and LT mutants have retained adjuvant activity when
given orally.

Mucosal tolerance and anti-inflammatory vaccines

One of the primary goals in developing effective therapies
against diseases caused by unwanted or tissue damaging
inflammatory immune responses, is to specifically suppress or
decrease to an acceptable level the intensity of un toward
immune reactions without affecting the remainder of the
immune system. Induction of tolerance in mature pathogenic
T cells represents an ideal form of specific immunotherapy in
the treatment of chronic inflammatory autoimmune disorders
and allergies.

Three main modes of peripheral tolerance induction by
antigens have been considered: parenteral administration of
antigens, parenteral administration of antigen analogs which
act as T-cell receptor antagonists, and mucosal administration
of antigens or so-called “oral tolerance”. Mucosal administra-
tion of antigen is in fact a long-recognized method of inducing
peripheral tolerance. The phenomenon, often referred to as
“oral tolerance” (because it was initially documented by the
effect of oral administration of antigen), is characterized by the
fact that animals fed or having inhaled an antigen become
refractory or have diminished capability to develop an immune
response when re-exposed to the same antigen introduced by
the systemic route, e.g. by injection. This effect is especially
pronounced for Th1 cell-mediated immune responses and is
regarded as an important natural physiological mechanism
whereby we avoid developing delayed-type hypersensitivity
reactions to dietary and airborne antigens, and products from
commensal microorganisms. Mucosally induced immunologi-
cal tolerance can affect all types of adaptive immune responses,
depending on the animal species, the age, the form and dose of
antigen, and the route of mucosal administration (enteric, buc-
cal, nasal, rectal, genital).

Mechanisms of tolerance after mucosal delivery of antigens

Mucosal uptake of antigens may result in the development of
immunity or tolerance, or even both, the decision being taken
in the epithelium or underlying lymphoid tissue and being
mainly determined by the nature and physico-chemical form
of the antigen.

Depending upon the dose of antigen administered, dele-
tion or anergy of antigen-specific T cells and/or expansion of
cells producing immunosuppressive cytokines (IL-4, IL-10 and
TGF-β) (reviewed in (73)), may result in decreased T-cell
responsiveness. It is interesting to note that the latter scenario
involves cytokines that are also known to promote IgA isotype
switching and IgA production, and is thus compatible with the
observation that secretory IgA antibody responses and systemic
T-cell tolerance may develop concomitantly (237). Because tolerance can be transferred by both serum and cells from tolerantized animals, it is possible that humoral antibodies (IgA?), circulating undegraded antigens or tolerogenic fragments and cytokines may act synergistically to confer T-cell unresponsiveness. Without excluding the above possibilities, another mechanism that may be considered could involve antigen-driven attraction of inflammatory T cells from the periphery into the mucosal microenvironment where they could be rendered anergic, functionally skewed, deleted or even ignored. This form of antigen-driven "anatomic deviation" would imply that inflammatory T cells activated in peripheral tissues exhibit a promiscuous migratory behaviour allowing their entry not only in systemic organs but also in mucosal tissues at the site of antigen uptake. The latter scenario has not yet been addressed experimentally but is compatible with studies showing that arthritogenic and diabetogenic T cells do express the cell surface mucosal integrin α4β7 whose ligand, the mucosal addressin cellular adhesion molecule (MadCAM-1), is also expressed in inflamed pancreas and synovial tissues. In this respect, it is also interesting to note that oral tolerization with a prototype soluble protein antigen has recently been shown to differentially affect the production by peripheral T cells of the β (C-C) chemokines MIP-1α and MCP-1 (238), which are potent chemoattractants for T cells.

Irrespective of effector mechanism(s) involved, a major question that arises is where and how tolerance is induced, be it suppression, anergy, deletion, ignorance and/or anatomical deviation. To date, very little is known regarding the mechanisms governing induction of mucosal tolerance, and especially the intracellular pathways of entry of tolerogens, the nature of APC elements involved, their tissue localization, and the characteristics of signals transduced from such cells to responding T cells. At variance with systemically administered antigens, antigens handled in mucosal tissues have already been subject to a variety of innate factors such as, e.g., proteases, acids, salts, mucins, that have altered their form prior to uptake. As a result of this "extratissular conditioning" different epitopes may be exposed and their uptake and/or processing may involve many different cell types.

The observation that mucosally induced systemic tolerance depends on an intact epithelial barrier (239, 240) suggests a central role for the epithelium. M cells have been shown to uptake a variety of particulate antigens such as viruses and bacteria, and to allow direct entry of invasive microorganisms in mucosal inductive sites. Such a pathway is thought to result in the induction of secretory IgA immune responses. Although the ability of M cells to serve as APCs appears to be poorly supported, these cells could still theoretically be involved in an abortive form of antigen presentation leading to tolerance induction. The role of absorptive epithelial cells, such as intestinal enterocytes, in tolerance induction has been underscored by several studies (reviewed in (241, 242)). Epithelial enterocytes express co-stimulatory molecules such as non-classical MHC class I (CD1d) molecules involved in antigen presentation to subpopulations of T cells and abnormal forms or levels of MHC class II molecules, leading to selective triggering of suppressive CD8+ T cells and/or abortive presentation to CD4+ T cells. In addition, epithelial enterocytes have also been shown to produce cytokines, such as IL-10 and TGF-β, which are particularly efficient at suppressing the inductive phase of CD4+ T-cell-mediated responses.

All known types of classical APCs, including DCs, macrophages and B cells, and even mast cells, have been shown to populate mucosal tissues but, because of their heterogeneity and of the difficulty in isolating pure subpopulations of APCs from mucosal tissues, their respective role in inducing tolerance has not yet been elucidated. Although activated B cells and tissue macrophages are powerful APCs for memory Th cells, evidence suggests that antigen presentation by resting B cells results in T-cell tolerance (243, 244). It should however be noted that B cells activated in vitro with bacterial lipopolysaccharide (LPS), a prominent component of the normal mucosal microflora, are capable of inducing tolerance when injected into naive hosts (244). Although functional DCs have been identified in mucosal tissues such as the Peyer's patches, the mesenteric lymph, the intestinal lamina propria and the airway mucosa (reviewed in (245)), their role in activating rather than suppressing naive T cells has received strongest support. Thus, DCs freshly isolated from the airway mucosa preferentially activate Th2 cells but can also mature into APCs capable of activating Th1 (246). Thus, airway DC cells could play a pivotal role in the cross-regulation of Th1- and Th2-driven responses. However, recent experiments with splenic dendritic cells have shown a differential capacity of these DC subpopulations to activate T cells, suggesting the existence of regulatory and immunostimulatory DC subsets, supporting the emergence of the concept of tolerogenic DCs (247). Further, treatment with Flt3 ligand which is known to expand DCs in vivo, has been reported to enhance oral tolerance (248). Interestingly, LPS, which is known to cause the rapid exit of DCs, has also been shown to enhance tolerance induction (249). This information places strong emphasis on the site of entry and on the intracellular pathway of processing of antigens administered to a mucous membrane in the induction of tolerance and/or immunity and calls for the need to develop vaccine formula-
Mucosal immunotherapy: potential and limitations

Since mucosally induced immunological tolerance is exquisitely specific to the antigen initially ingested or inhaled, and thus does not influence the development of systemic immune responses against other antigens, its manipulation has become an increasingly attractive strategy for preventing and possibly treating illnesses associated or resulting from the development of adverse immunological reactions against self and non-self antigens. The approach has been considered for preventing or treating hypersensitivities to common allergens (250–252). The phenomenon of mucosally induced systemic tolerance has likewise been utilized to suppress immune responses against self antigens. It has thus been possible to delay the onset and to decrease the intensity of experimental autoimmune diseases in a variety of animal systems by mucosal deposition of auto-antigens onto the intestinal (by feeding) or the respiratory mucosa (by aerosolization or intranasal instillation of antigens) (reviewed in (73)). For instance, oral administration of collagen type II has been shown to delay the onset of autoimmune arthritis. Similarly, it has been possible to suppress an experimental form of autoimmune uveoretinitis by oral administration of the retinal S-antigen.

Although the above examples indicate that mucosal administration of foreign as well as self antigens offers good promise for inducing specific immunologic tolerance, the applicability of this approach in human medicine remains limited by practical problems. Indeed, to be clinically broadly applicable, mucosally induced immunological tolerance must also be effective in patients in whom the disease process has already established itself and/or in whom potentially tissue-damaging immune cells already exist. This is especially important when considering strategies of tolerance induction in patients suffering from or prone to an autoimmune disease or an allergic condition. Current protocols of mucosally induced tolerance have had limited success in suppressing the expression of an already established state of systemic immunological sensitization (253, 254). This may partly explain the disappointing results of recent clinical trials of oral tolerance in patients with multiple sclerosis and rheumatoid arthritis.

In addition, and by analogy with mucosal anti-infectious vaccines, induction of mucosal tolerance requires administration of massive amounts of antigens or prolonged administration of relatively smaller amounts of antigens which are then only effective in rather narrow dose ranges. As for conventional vaccines, efforts have recently been devoted to the construction of novel or improved formulations to induce mucosal tolerance. In this respect, the use of mucosal lectins endowed strong immunomodulating properties, such as cholera and E. coli heat-labile enterotoxin B subunits, as carrier for mucosal delivery of tolerogenic peptides has received considerable attention during the past five years as described below.

Cholera toxin B subunit as mucosal carrier-immunomodulating system for antipathological vaccination

Recent studies have shown that physical coupling of an antigen to CT-B led to unexpected effects: when given by various mucosal routes, CT-B induced a strong mucosal IgA immune response to itself and in some cases also to the conjugated antigen, but instead of abrogating systemic tolerance enhanced it profoundly (229). Based on this finding and on the results of other experiments with a variety of antigens (255), there is good reason to believe that such a system may be advantageous for inducing peripheral tolerance. First, it minimizes by several hundred-fold the amount of antigen/tolerogen and drastically reduces the number of doses that would otherwise be required by reported protocols of orally-induced tolerance. Second, but most important, this strategy appears to be applicable for suppressing the expression of an already established state of systemic immune sensitization. Here, we shall summarize the results of studies using this approach as a means to prevent or treat pathological immune responses associated with experimental autoimmune diseases, type I allergies, and allograft rejection.

Treatment of organ-specific autoimmune diseases

Mucosal administration of relevant autoantigens linked to CT-B could inhibit the development of clinical disease in animal models of experimentally inducible autoimmune diseases, such as allergic encephalomyelitis (256) and collagen-induced arthritis (257). In the latter model, nasal administration of a collagen type II–CT-B conjugate could inhibit disease progression, even when treatment was initiated after onset of clinically overt disease. Furthermore, oral treatment of female NOD mice with a CT-B–insulin conjugate could suppress type I diabetes (258), a model of spontaneous autoimmune disease, even when given as late as 15 weeks post-birth (that is at a time when all mice have evidence of insulinitis). Taken together, these observations indicate that CT-B-driven mucosal tolerance can affect not only the afferent but also the efferent phase of systemic T-cell-mediated inflammatory responses.

Depending on the nature of the conjugated antigen, the route of administration (oral, nasal) of the conjugate, and the animal species used, this type of treatment variably affected the capacity of lymph node T cells to produce Th1 or Th2 cytokines.
The most striking observation in all three models of autoimmune diseases tested was the finding that treatment with CT-B-antigen suppressed leukocyte infiltration into the target organ. This suggests that the mechanisms governing induction of tolerance by feeding or inhaling CT-B-linked antigens may involve modifications of the migratory behavior of inflammatory cells.

Prevention of graft rejection
By coupling thymocytes to cholera B subunit and feeding this conjugate to mice, it has been possible to significantly prolong the survival of transplanted hearts in allogeneic mouse recipients (unpublished results). Recently, feeding CT-B-derivated donor keratinocytes has been shown to prevent corneal allograft rejection in mice (259).

Prevention of type I allergies
The possibility of preventing type I allergic reactions by mucosal administration of a prototype allergen linked to a mucosal vector with intrinsic immunomodulating properties has also recently been examined in a mouse model of ovalbumin (OVA)-induced allergic reactions. Thus, mice nasally administered with OVA conjugated to E. coli LT-B prior to allergic sensitization showed suppressed skin DTH responses to OVA and also suppressed serum IgE antibody responses to the inhaled allergen (260). Further, these mice showed markedly decreased anaphylactic responses to intravenously administered OVA. Taken together, the latter observations indicate that under certain conditions, mucosal administration of soluble protein together with an immunomodulating mucosal vector can suppress both systemic Th1- and Th2-driven responses. The fact that the same type of regimen is also known to favor S-IgA responses in mucosal tissues makes this concept even more attractive since IgA is known to be non-phlogistic and could theoretically outcompete IgE for binding to a given allergen. However, it should also be pointed out that suppression of Th2-driven responses such as IgE antibody responses appears considerably more difficult to achieve than corresponding Th1 responses (e.g. DTH) in an animal already systemically sensitized to the allergen; in the latter situation, mucosal treatment with CT-B-conjugated allergen required prolonged administration of the conjugate and was effective only with certain allergens (C. Rask, J. Holmgren, C. Czerkinsky, unpublished observations).

Mucosal vaccines for simultaneous induction of anti-infectious and antipathological immunity
Somewhat surprisingly, vaccinologists in general and mucosal immunologists in particular have usually believed that a reciprocal relationship exists between induction of immunity and tolerance. The observation that mucosal immunity, which is typified by secretory IgA antibodies, may develop concomitantly with systemic immunological tolerance has led to the belief that vaccines against mucosal pathogens should primarily stimulate immunity without inducing tolerance. However, from a theoretical standpoint, the possibility to manipulate the mucosal immune system towards both immunity and tolerance appears rather attractive when considering strategies aimed at protecting the host from colonization or invasion by mucosal pathogens but also to interfere with the development of potentially harmful systemic immunological reactions against the same pathogens or their products.

The notion that immunological tolerance may provide the host with a protective mechanism against an infectious disease has been elegantly illustrated by recent studies in transgenic mice. Whereas mice from a susceptible (BALB/c) background develop an early Th2-driven IL-4 response and ultimately succumb to their infection with Leishmania major, mice rendered tolerant by transgenic expression in the thymus of LACK, a protective surface antigen of Leishmania, fail to produce this early response and resolve their infection (261). Very recently, tolerization of post-thymic, mature parasite-specific T cells could also be accomplished in the periphery after nasal administration of as little as 10 μg of L major LACK antigen conjugated to CT-B (262). Such treatment markedly delayed the onset of lesion development in infected mice and reduced parasite burden in the skin and draining lymph nodes of infected mice.

Similar findings have also been observed in mice that had already been infested with the parasitic trematode, Schistosoma mansoni (263) and treated with a CT-B-parasite conjugate vaccine. Thus, nasal treatment of mice with S. mansoni glutathione S-transferase (GST) conjugated to CT-B suppressed granuloma formation and decreased parasite burden and egg deposition in the liver of infested animals. Protection with this nasal CT-B-GST vaccine was associated with decreased hepatic production of IFN-γ, IL-5 and IL-3 but apparently intact IL-4 production. Most importantly, such treatment could significantly prolong the survival of animals, even when initiated as late as 6 weeks after initial infection, that is at a time when liver granulomatous reactions are most pronounced.

While this type of approach has only been attempted in two parasitic diseases, there are obvious microbial diseases which could theoretically benefit from the concomitant induction of S-IgA immune responses and downregulation of local T-cell-driven immunopathology. Examples of such diseases include gastroduodenal ulcers caused by Helicobacter pylori, genital ulcers caused by papilloma viruses, broncho-pneumonitis...
induced by parainfluenzae viruses and respiratory syncytia virus, or chronic pelvis inflammatory disease, trachoma and urethritis caused by Chlamydia pneumoniae.

Other mucosal delivery systems for induction of tolerance

Most of the work published so far on induction of peripheral tolerance after mucosal administration of antigens has involved the use of free antigens and more recently that of antigens co-administered with CT-B or analogs. However, the possibility of developing improved tolerogenic formulations based on expression of selected antigens and/or immunomodulating cytokines and chemokines in appropriate vectors, e.g. lactobacilli, edible plants (264), or corresponding genes in plasmid DNA (265), are now being actively addressed.

Mucosally induced tolerance has the virtue of being a powerful natural and specific protective mechanism against adverse immune reactions that may result from mucosal intake of immunogenic matters. This property may be utilized to treat disorders associated with untoward immune responses to self and non-self antigens, such as certain autoimmune diseases, allergic reactions, and graft rejection (Table 1). Hence, mucosal immunomodulation via appropriate delivery of tolerogenic compounds may be where the future of anti-inflammatory vaccines lies.

References

1. Liew FY, Russell SM, Appleyard G, Brand CM, Beale J. Cross-protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T-cell reactivity. Eur J Immunol 1984; 14:350–356.

2. Maraner MB, Kaetzel CS, Lamot ME, Fletcher D, Neudorf JG. Intracellular neutralization of virus by immunoglobulin A antibodies. Proc Natl Acad Sci USA 1992; 89:6901–6905.

3. Alley CD, Mestecky J. The mucosal immune system. In: Birdland G, Calvert JE, eds. Immunoglobulins in human disease. Oxford: Oxford University Press; 1988. p. 222–254.

4. Allansmith MR, McClellan BH, Butterworth M, Maloney JR. The development of immunoglobulin in normal and graft-versus-host conditions. J Exp Med 1978:148:1661–1667.

5. Davies MD, Parrott DM. The early appearance of specific cytotoxic T cells in murine gut mucosa. Clin Exp Immunol 1980; 42:773–179.

6. MacDermott RP, Franklin GO, Jenkins KM, Kodner IJ, Nash GS, Weinrieb IJ. Human intestinal mononuclear cells. I. Investigation of antibody-dependent, lectin-induced and spontaneous cell-mediated cytotoxic capabilities. Gastroenterology 1980; 78:47–56.

7. Davies MD, Parrott DM. Cytotoxic T cells in small intestine, epithelial, lamina propria and lung lymphocytes. Immunology 1981; 44:367–371.

8. Guy-Grand D, Griscelli C, Vassalli P. The mouse gut T lymphocyte: a novel type of T cell. Nature, origin, and traffic in mice in normal and graft-versus-host conditions. J Exp Med 1978:148:1661–1667.

9. Davies MD, Parrott DM. Cytotoxic T cells in small intestine, epithelial, lamina propria and lung lymphocytes. Immunology 1981; 44:367–371.

10. Tagliabue A, Latini W, Soldateschi D, Boraschi D. Natural killer activity of gut mucosal lymphoid cells in mice. Eur J Immunol 1981; 11:919–922.

11. Nauss KM, Pavlina TM, Kumar V, Newberne PM. Functional characteristics of lymphocytes isolated from the rat large intestine. Response to T-cell mitogen and natural killer cell activity. Gastroenterology 1984; 86:468–475.

12. Ernst PB, Refus AD, Bienenstock J. Leukocytes in the intestinal epithelium: An unusual immunologic compartment. Immunol Today 1985; 6:50–55.

13. Smyth MJ, Trapani JA. The relative role of lymphocyte granule exocytosis versus death-receptor-mediated cytotoxicity in viral pathophysiology. J Virol 1999; 72:1–9.

14. London SD, Rubin DH, Cebra JJ. Gut mucosal immunization with reovirus serotype I/L stimulates virus-specific cytotoxic T cell precursors as well as IgA memory cells in Peyer's patches. J Exp Med 1987; 165:830–847.

15. Offit PA, Cunningham SL, Doudrik KL. Memory and distribution of virus-specific cytotoxic T lymphocytes (CTLs) and CTL precursors after rotavirus infection. J Virol 1991; 65:1318–1324.

16. London SD, Cebra-Thomas JA, Rubin DH, Cebra JJ. CD8 lymphocyte subpopulations in Peyer's patches induced by rotavirus serotype I infection. J Immunol 1990; 144:3187–3194.

17. George A, Kost SI, Witzleben CL, Cebra JJ, Rubin DH. Reovirus-induced liver disease in severe combined immunodeficient (SCID) mice. A model for the study of viral infection, pathogenesis, and clearance. J Exp Med 1990; 171:919–934.

18. Cuff CE, Cebra CK, Rubin DH, Cebra JJ. Developmental relationship between cytotoxic T cells of gut mucosal lymphocytes and Peyer's patch lymphocytes. Eur J Immunol 1993; 23:1333–1339.

19. Issszikits TB. The response of gut-associated T lymphocytes to intestinal viral immunization. J Immunol 1984; 133:2955–2960.
22. Buzoni-Gare, D, Lepage, AC, Dimitr-Poiisson, IH, Bout, DT, Kasper L.H. Adoptive transfer of gut intraepithelial lymphocytes protects against murine infection with Toxoplasma gondii. J Immunol 1997;158:5883–5889.

23. Offit PA, Dudzik KI. Rotavirus-specific cytotoxic T lymphocytes passively protect against gastroenteritis in suckling mice. J Virol 1990;64:6325–6328.

24. Dharakul T, et al. Immunization with baculovirus-expressed recombinant rotavirus proteins VP1, VP4, VP6 and VP7 induces CD8+ T lymphocytes that mediate clearance of chronic rotavirus infection in SCID mice. J Immunol 1991;145:5928–5932.

25. Franco MJ, Garren HB. Role of B cells and cytotoxic CD8+ T lymphocytes in clearance of and immunity to rotavirus infection in mice. J Virol 1995;69:7800–7806.

26. Franco MA, Tan C, Rott IS, Van Cut J, McGhee Jr, Greenberg HB. Evidence for CD8+ T-cell immunity to murine rotavirus in the absence of perforin, fas and γ interferon. J Virol 1997;71:479–486.

27. Burns JW, Siadat-Pajouh M, Krishnan AA, Greenberg HB. Protective activity of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 1996;272:104–107.

28. Belyakov IM, et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccine challenge. Proc Natl Acad Sci USA 1998;95:1709–1714.

29. Anderson MJ, Patterson JS, Cureton RL, Argent S, Heath RB. The role of host responses in the recovery of mice from Sendai virus infection. J Gen Virol 1980;46:5052–5060.

30. Johnson RA, Prince GA, Suhl HS. Respiratory syncytial virus infection in cyclophosphamide-treated cotton rats. Infect Immun 1982;37:369–373.

31. Bender BS, Croghan T, Zhang L, Small PA Jr. Transgenic mice lacking class I major histocompatibility complex-restricted CD8+ T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med 1992;175:1143–1145.

32. Crowe Jr. Host responses to respiratory virus infection and immunization. Curr Top Microbiol Immunol 1999;227:191–214.

33. Allan W, Tati Z, Cleary A, Doherty PC. Cellular events in the lymph node and lung of mice with influenza. Consequences of depleting CD4+ T cells. J Immunol 1990;144:3980–3986.

34. Eichberger M, Allan W, Zajist M, Jaenisch R, Doherty PC. Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J Exp Med 1991;174:875–880.

35. Carding SR, Allan W, Kyes S, Hayday A, Bottomly K, Doherty PC. Latent dominance of the inflammatory process in murine influenza by γδ T cells. J Exp Med 1990;172:1225–1231.

36. Mooi J, McCarthy CA, Clark ME, Hall CB. Respiratory syncytial virus infection in C57BL/6 mice: Clearance of virus from the lungs with virus-specific cytotoxic T cells. J Virol 1991;65:4494–4497.

37. Nicholas J, Rubino KL, Levey ME, Meyer AL, Collins PL. Cytotoxic T cell activity against the 22-kDa protein of human respiratory syncytial virus (RSV) is associated with a significant reduction in pulmonary RSV replication. Virology 1991;182:664–672.

38. Graham BS, Buxton LA, Wright PF, Karzon DT. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 1991;88:1026–1033.

39. Graham BS, Henderson GS, Tang YW. Lu X, Neuzil KM, Colley DG. Priming immune determinates T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 1993;151:2032–2040.

40. Miller CJ. Mucosal transmission of simian immunodeficiency virus. Curr Top Microbiol Immunol 1994;188:107–112.

41. Lowman BL, Miller CJ, McChesney CB. Avian cytotoxic T lymphocytes in various mucosa of simian immunodeficiency virus-infected rhesus monkeys. J Immunol 1995;155:5855–5860.

42. Miller CJ, et al. Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from viremia and histologic injury after inoculation of pathogenic SIV_CP139. J Virol 1997;71:1911–1921.

43. Mueser L, Hu Y, Eckert L, Christensen M, Karchmer T, McElrath MJ. HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women. J Exp Med 1997;185:293–303.

44. Buccheri BC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996;272:60–66.

45. Weinberg AD, English M, Swain SL. Distinct regulation of lymphokine production is found in fresh versus in vitro primed murine helper T cells. J Immunol 1990;144:1800–1807.

46. Powers GD, Abbas AK, Miller RA. Frequencies of IL-2- and IL-4-secreting T cells in naïve and antigen-stimulated lymphocyte populations. J Immunol 1988;140:3352–3357.

47. Daynes RA, Araneo BA, Dowell TA, Huang K, Dudley D. Regulation of murine lymphokine production is via. IL-3. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function. J Exp Med 1998;170:979–986.

48. Hsieh CA, Macatonia SE, Tripp CS, Wolf SF, O’Garra A, Murphy KM. Development of Th1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993;260:547–549.

49. Trinchieri G, Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13:251–276.

50. Snapper CM, Paul WE. Interferon-γ and B cell stimulatory factor-1 reciprocal regulates Ig isotype production. Science 1987;236:944–947.

51. Yoshimoto T, Paul WE. CD4+ CD45R0+ NK1.1+ T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med 1994;179:1285–1295.

52. Yoshimoto T, Bendelac A, Watson C, Hu-Li J, Paul WE. Role of NK1.1+ T cells in a Th2 response and in immunoglobulin E production. Science 1995;270:1845–1847.

53. Coffman RL, Varkila K, Scott P, Chatelain P. Role of cytokines in the differentiation of CD4+ T-cell subsets in vivo. Immunol Rev 1991;123:189–207.

54. Mosmann TR. The role of helper T-cell products in mouse B-cell differentiation and isotype regulation. Immunol Rev 1988;102:5–28.

55. Mosmann TR, Coffman RL. Th1 and Th2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145–173.

56. Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4+ T cells. J Allergy Clin Immunol 1994;94:1195–1202.

57. Schooley KA, Coffman RL, Mosmann TR, Paul WE. Lymphokine control of in vivo immunoglobulin isotype selection. Annu Rev Immunol 1990;8:303–333.

58. Esler C, Radbruch A. Immunoglobulin class switching: Molecular and cellular analysis. Annu Rev Immunol 1990;8:717–735.
95. Hopkins S, et al. A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization. Infect Immun 1995;63:3279–3286.

96. Moldoveanu Z, Russell MW, Wu HY, Huang W-Q, Comans RW, Mestecky J. Compartmentalization within the common mucosal immune system. Adv Exp Med Biol 1995;371:97–102.

97. Nardelli-Haefliger D, et al. Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain. Infect Immun 1996;64:5219–5224.

98. Hordnes K, Tynning T, Kvam AI, Johnsson R, Haneberg B. Colonization in the rectum and uterine cervix with group B streptococci may induce specific antibody responses in cervical secretions of pregnant women. Infect Immun 1996;64:1643–1652.

99. Kozlowski PA, Cu-Uvin S, Neutra MR, Flanagan TP. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun 1996;65:1387–1394.

100. Eriksson K, et al. Specific-antibody-secreting cells in the rectums and genital tracts of non-human primates following vaccination. Immunol Infect Immun 1998;66:5889–5896.

101. Saito H, et al. Generation of intestinal T cells from progenitors residing in gut cryptopatches. Science 1998;280:275–278.

102. Lubeck MD, et al. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration. AIDS Res Hum Retroviruses 1994;10:1443–1449.

103. Quinding-Järbrink M, Granström T, Lindgren J, Czerkinsky C. Induction of compartmentalized B-cell responses in human tonsils. Infect Immun 1995;63:853–857.

104. Gallie LH, Rosenthal KL. Specific secretory immune responses in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine 1995;13:1859–1959.

105. Gallie LH, Johnson DC, Graham FL, Rosenthal KL. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex glycoprotein B. J Infect Dis 1993;168:622–629.

106. Pal S, Peterson EM, de la Maza LM. Intranasal immunization induces long-term protection in mice against a Chlamydia trachomatis genital challenge. Infect Immun 1996;64:5341–5348.

107. Russell MW, Moldoveanu Z, White PL, Sibert GJ, Mestecky J, Michael SK, Saliva. nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the cholera toxin B subunit. Infect Immun 1996;64:1272–1282.

108. Di Tommaso A, et al. Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant. Infect Immun 1996;64:974–979.

109. Staas HF, Nichols WG, Palker TJ. Systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A). J Immunol 1996;157:462–472.

110. Bergquist C, Johansson EL, Lagergard T, Holmgren J, Rudin A. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun 1997;65:2676–2684.

111. Johansson EL, Rask C, Fredriksson M, Eriksson K, Czerkinsky C, Holmgren J. Antibodies and antibody-secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates. Infect Immun 1998;66:514–20.

112. Hameleers DM, Stoop AE, van der Ven I, Biewenga J, van der Baan S, Sminia T. Intrarectal and subepithelial cells in the human nasal mucosa. Int Arch Allergy Appl Immunol 1998;110:17–22.

113. Graeme-Cook F, Bhan AK, Harris NL. Immuno-histochemical characterization of intraepithelial and subepithelial mononuclear cells of the upper airways. Am J Pathol 1993;143:1416–22.

114. Kupfer CF, Hameleers DM, Bruining J, van der Ven I, Biewenga J, Smirna T. Lymphoid and non-lymphoid cells in nasal-associated lymphoid tissue (NALIT) in the rat. An immunohistochemical study. Cell Tissue Res 1990;259:371–377.

115. van der Ven I, Smirna T. The development and structure of mouse nasal-associated lymphoid tissue: an immuno- and enzyme-histochemical study. Reg Immunol 1993;5:69–75.

116. Ogra PL. Effect of tonsillectomy and adenoidectomy on nasopharyngeal antibody response to poliovirus. N Engl J Med 1979;284:59–64.
129. Gizurarson G, Jonsdottir VM, Heron I. Intranasal administration of diphtheria toxoid. Selecting antibody isotypes using formulations having various lipophilic characteristics.

Vaccine 1995;13:617–621.

130. Michalek SM, Eldridge JH, Curtiss III R, Rosenthal KL. Antigen delivery systems: new approaches to mucosal immunization. In: Ogra PL, Mestecky J, Linnemann ME, Strober W, McGhee JR, ed. Handbook of mucosal immunology. San Diego: Academic Press; 1994. p. 373–390.

131. Gould-Fogerite S, et al. Lipid matrix-based subunit vaccines: a structure-function approach to oral and parenteral immunization.

AIDS Res Human Retroviruses 1994;10:599–5103.

132. Eldridge JH, Meulbroek JA, Slaas JK, Tice TR, Michalek SM, Eldridge JH, Curtiss III R. Intranasal and oral administration and induce a disseminated mucosal immune response.

Curr Opin Immunol 1992;4:568–571.

133. Duncan JD, Gilley RM, Schaffir DP, Eldridge JH, Meulbroek JA, Slaas JK, Tice TR, Michalek SM, Eldridge JH, Curtiss III R. Mucosal vaccines. San Diego: Academic Press; 1996. p. 159–173.

134. Mestecky J, Eldridge JH. Targeting and controlled release of antigens for the effective induction of secretory antibody responses.

Adv Exp Med Biol 1989;251:191–202.

135. Duncan JD, Gilley RM, Schafer DP, Moldoveanu Z, Mestecky J, Poly (lactide-co-glycolide) microencapsulation of vaccines for mucosal immunization. In: Kiyono H, Ogra PL, McGhee JR, eds. Mucosal vaccines. San Diego: Academic Press; 1994. p. 373–390.

136. Mestecky J, Eldridge JH. Targeting and controlled release of antigens for the effective induction of secretory antibody responses.

Curr Opin Immunol 1991;3:492–495.

137. Mestecky J, et al. Current options for vaccine delivery systems by mucosal routes. J Controlled Release 1997;48:243–257.

138. McKenzie SJ, Halsey JR. Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response. J Immunol 1984;133:1818–1834.

139. De Aizpurua HI, Russell-Jones GJ. Oral vaccination: Identification of classes of proteins that provoke an immune response upon oral feeding.

J Exp Med 1988;167:440–451.

140. Czerkinsky C, Russell MW, Lycke N, Lindblad M, Holmgren J. Oral administration of a toxoplasma antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues. Infect Immun 1989;57:1072–1077

141. Bergquist C, Lagergard T, Lindblad M, Holmgren J. Local and systemic responses to dextran-cholera toxin B subunit conjugates. Infect Immun 1995;63:2021–2025.

142. Mestecky J, Holmgren J. Recombinant system for overexpression of cholera toxin B subunit and alkaline phosphatase as carriers for oral vaccines. Infect Immun 1993;61:48–55.

143. Sanchez J, Holmgren J. Recombinant system for overexpression of cholera toxin B subunit and alkaline phosphatase as carriers for oral vaccines. Infect Immun 1992;60:4915–4924.

144. Haji-shengallis G, Hollingshead SK, Koga T, Russell MW. Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits. J Immunol 1995;154:4322–4332.

145. Sultan F, Jin LL, Jobling MG, Holmes RK, Stanley SL Jr. Mucosal immunogenicity of a cholera toxin-like molecule containing the A2 domain of cholera toxin. Infect Immun 1994;66:462–468.

146. Moxon RE. Applications of molecular microbiology to vaccinology. Lancet 1991;330:1240–1244.

147. Piotkin SA. Vaccination in the 21st century. In: Gard AS, ed. Immunization science. New York: Marcel Dekker; 1992. p. 105–108.

148. Curtis R, Kelly SM, Hassan JO. Live oral avirulent Salmonella vaccines. Vet Microbiol 1993;37:397–405.

149. Doggett TA, Brown PK. Attenuated Salmonella as vectors for oral immunization. In: Kiyono H, Ogra PL, McGhee JR, eds. Mucosal vaccines. San Diego: Academic Press; 1994. p. 105–108.

150. Chatfield S, Roberts M, Londono P, Cropley I, Doucet G, Dougan G. The development of oral vaccines based on live attenuated Salmonella strains. In: Kiyono H, Ogra PL, McGhee JR, eds. Mucosal Vaccines. San Diego: Academic Press; 1994. p. 27–41.

151. Schoedel F, Curtiss R. Oral vaccine carriers. Dev Biol Stand 1995;84:245–253.

152. Yang DM, Fairweather N, Butterly IL, Mcmaster W, Kabir LP, Liew FY. Oral Salmonella typhimurium (AToA) vaccine expressing a major leishmanial surface protein (gp 63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis.

J Immunol 1994;150:2281–2285.

153. Okahashi N, et al. Oral immunization of interleukin-1 (IL-1) knockout mice with a recombinant Salmonella strain or cholera toxin reveals that CD4+ Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses.

Infect Immun 1996;64:1516–1525.

154. Russell MW. Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits. J Immunol 1995;154:4322–4332.

155. Baton MA, Brown PK. Attenuated Salmonella as vectors for oral immunization. In: Kiyono H, Ogra PL, McGhee JR, eds. Mucosal vaccines. San Diego: Academic Press; 1994. p. 105–108.

156. Yang DM, Fairweather N, Butterly IL, Mcmaster W, Kabir LP, Liew FY. Oral Salmonella typhimurium (AToA) vaccine expressing a major leishmanial surface protein (gp 63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis.

J Immunol 1994;150:2281–2285.

157. Okahashi N, et al. Oral immunization of interleukin-1 (IL-1) knockout mice with a recombinant Salmonella strain or cholera toxin reveals that CD4+ Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses.

Infect Immun 1996;64:1516–1525.

158. Graham FL. Use of human adenovirus-based vectors for antigen expression in animals. J Gen Virol 1989;70:429–434.

159. Wilson JM. Adenoviruses as gene-delivery vehicles. N Engl J Med 1996;334:1185–1187.

160. Graham FL, Smiley J, Russell WC, Nairn R. Characterization of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977;36:59–74.

161. Gallichan WS, Rosenthal KL. Long-term immunity and protection against herpes simplex virus type 2 in the murine female genital tract after mucosal but not systemic immunization.

J Infect Dis 1998;177:1155–1161.

162. Gallichan WS, Rosenthal KL. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization.

J Exp Med 1996;184:1879–1890.

163. Buge SL, et al. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge.

J Virol 1997;71:8531–8541.
164. Prevec L, Campbell JB, Christie BS, Belbeck L, Graham FL. A recombinant human adenovirus vaccine against rabies. J Infect Dis 1990;161:27–30.

165. Hsu KH, et al. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 5, 6, and 7 vectors in dogs and a chimpanzee. J Infect Dis 1992;166:769–775.

166. Tacket CO, et al. Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine. Vaccine 1993;10:673–676.

167. Baca-Estrada ME, Liang X, Babik LA, Yoo D. Induction of mucosal immunity in cotton rats to haemagglutinin-esterase glycoprotein of bovine coronavirus by recombinant adenovirus. Immunology 1995;86:134–140.

168. Kagami H, et al. Repetitive adenovirus administration to the parotid gland: role of immunological barriers and induction of tolerance. Hum Gene Ther 1998;10:305–313.

169. Brocker B, et al. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature 1991;354:520–522.

170. Klent MP, et al. Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature 1984;312:163–166.

171. Meitin CA, Bender BS, Small PA Jr. Enteric immunization of mice against influenza with recombinant vaccinia. Proc Natl Acad Sci USA 1994;91:11187–11191.

172. Ramsay AJ, Kohonen-Corish M. Interleukin-5 vaccine vectors in mice. Vaccine 1996;14:1083–1087.

173. Anderson MJ, Porter DC, Moldoveanu Z, Defective adenovirus and Nyvac poxvirus as vaccine vectors for mucosal immunization. Vaccine 1994:12:1032–1040.

174. Morrow CD, Novak MJ, Ansardi DC, Porter DC, Moldoveanu Z. Recombinant viruses as vectors for mucosal immunity. Curr Top Microbiol Immunol 1999;236:255–273.

175. Caley I, et al. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J Virol 1997;71:3031–3038.

176. Davis NL, Brown KW, Johnston RE. A viral vector vaccine that expresses foreign genes in lymph nodes and protects against mucosal challenge. J Virol 1996;70:3781–3787.

177. Pushko P, Parker M, Ludwig GV, Davis NL, Johnston RE, Smith JF. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vivo and immunization against heterologous pathogens in vivo. Virology 1997;239:389–401.

178. Tang S, van Rij R, Silvera D, Andino R. Toward a poliovirus-based simian immunodeficiency virus vaccine: correlation between genetic stability and immunogenicity. J Virol 1997;71:7841–7850.

179. Anderson MJ, Porter DC, Moldoveanu Z, Vaccination: an update. Proc Natl Acad Sci USA 1993;90:11478–11482.

180. Wang B, et al. Gene inoculation generates immune responses against HIV-1. Proc Natl Acad Sci USA 1993;90:4156–4160.

181. Pushko P. Parker M, Ludwig GV, Davis NL, Moldoveanu Z, Recombinant viruses as vaccine vectors in mice. J Virol 1997:71:3138–3145.

182. Etchart N, Buckland R, Liu MA, Wild TF, Kaiserman D. Class I-restricted T-cell induction by mucosal immunization with naked DNA encoding measles virus haemagglutinin. J Gen Virol 1997:78:1577–1580.

183. Baragazzi ML, et al. Safety and immunogenicity of intramuscular and intravaginal delivery of HIV-1 DNA constructs to infant chimpanzees. J Med Primatol 1997;26:27–33.

184. McCluskie MJ, Chu Y, Jia JL, Jessee J, Gelyshu G, Davis HL. Direct gene transfer to the respiratory tract of mice with pure plasmid and lipid-formulated DNA. Antisense Nucleic Acid Drug Dev 1998;8:401–414.

185. Okada E, et al. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J Immunol 1997;159:3638–3647.
204. Darji A, et al. Oral somatic transgene vaccination with a DNA-polypeptide chimera induces protective immunity. J Immunol 1999;162:254-262.

205. Klavinskis LS, Barnfield C, Gao L, Parker S. Intranasal immunization with a DNA-polypeptide chimera induces protective immunity in the female genital and rectal tracts. J Immunol 1999;162:507-517.

206. Sasaki S, et al. Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-polypeptide chimera. J Infect Dis 1999;179:526-532.

207. Bender A, Bui LK, Feldman MA, Larson M, Hindwaj N. Inactivated influenza virus vaccination with a DNA-polypeptide chimera induces protective immunity in the female genital and rectal tracts. J Immunol 1999;162:507-517.

208. Chattergoon MA, Robinson TM, Boyer JD, Ca,sares S, Inaba K, Brumeanu TD, J.B, Cobon GS, eds. New generation vaccines. J Immunol 1999:162:254-262.

209. DL, Stockinger B. DNA vaccination: principles and practices. J Clin Invest 1999:103:1311-1317.

210. Louie T, Steinman RM. Dendritic cells and the control of immunity. J Immunol 1999:162:254-262.

211. Mayordomo JI, et al. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Semin Immunol 1999;11:15-26.

212. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999;50:507-529.

213. Brenchereau J, Steinman RM. Dendritic cells and the control of immunity. J Clin Invest 1999:103:1311-1317.

214. Spangier BD. Structure and function of dendritic cells. Annu Rev Med 1999:50:507-529.

215. Proctor JC, Caldwell HD. Vaccination against chlamydial genital tract infection after immunisation with dendritic cells pulsed with nonviable chlamydiae. J Exp Med 1999;188:809-818.

216. Brossart P, Goldrath AW, Butz EA, Martin S, Bevan MJ. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 1999;162:3270-3276.

217. Fuksa S, Magnani JR, Twiddy EM, Holmes RK, Ginsburg V. Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LT-I and LT-IIa. J Infect Dis 1999;179:1614-1623.

218. Brossart P, Goldrath AW, Butz EA, Martin S, Bevan MJ. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 1999;162:3270-3276.

219. Louie T, Steinman RM. Dendritic cells and the control of immunity. J Immunol 1999:162:254-262.

220. Mayordomo JI, et al. Bone marrow-derived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Semin Immunol 1999;11:15-26.

221. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999;50:507-529.

222. Brossart P, Goldrath AW, Butz EA, Martin S, Bevan MJ. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 1999;162:3270-3276.

223. Fuksa S, Magnani JR, Twiddy EM, Holmes RK, Ginsburg V. Comparison of the carbohydrate-binding specificities of cholera toxin and Escherichia coli heat-labile enterotoxins LT-I and LT-IIa. J Infect Dis 1999;179:1614-1623.

224. Brossart P, Goldrath AW, Butz EA, Martin S, Bevan MJ. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J Immunol 1999;162:3270-3276.

225. Munoz E, Zubiaga AM, Marrow M, Sauer NP, Huber BT. Cholera toxin discriminates between T helper 1 and 2 cells in T cell receptor-mediated activation: role of cAMP in T cell proliferation. J Exp Med 1992:175:131-138.

226. Klavinskis LS, Barnfield C, Gao L, Parker S. Intranasal immunization with a DNA-polypeptide chimera induces protective immunity in the female genital and rectal tracts. J Immunol 1999;162:507-517.

227. Snider DP, Marshall, JS, Perdue MH, Liang H. Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin. J Immunol 1999;163:647-657.

228. Wilson AD, Bailey M, Williams NA, Stokes CR. The in vivo production of cytokines by mucosal lymphocytes immunized by oral administration of key-hole limpet hemocyanin using cholera toxin as an adjuvant. J Infect Dis 1991;163:333-339.

229. Sun JH, Holmgren J, Czerkinsky C. Cholera toxin B subunit: an effective transmucosal carrier delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci USA 1994:91:10795-10799.

230. Bowen JC, Nair SK, Reddy R, Rouse BT. Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens. J Immunol 1994;152:338-342.

231. Lycke N, Tsuji T, Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol 1992;22:2277-2281.

232. Takahashi I, et al. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli heat-labile enterotoxin. J Infect Dis 1996:173:627-635.

233. Douce G, et al. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci USA 1995;92:1644-1648.

234. Dickinson B, Clements JD. Dissociation of Escherichia coli heat-labile enterotoxin adjuvancy from ADP-ribosyltransferase activity. Infect Immun 1995;63:1617-1623.

235. Yamamoto S, et al. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci USA 1997;94:5267-5272.

236. Yamamoto S, et al. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci USA 1997;94:5267-5272.
237. Challacombe SJ, Tomasi TB Jr. Systemic tolerance and secretory immunity after oral immunization. J Exp Med 1980;152:1459–1472.

238. Karpus WJ, Lukacs NW. The role of chemokines in oral tolerance: abrogation of nonresponsiveness by treatment with anti-MCP-1. Ann N Y Acad Sci 1996;778:133–142.

239. Strobel S, Mowat AM, Drummond HE, Karpus WJ, Lukacs NW. The role of small B cells as antigen-presenting cells in the induction of oral tolerance. J Immunol 1998;160:5815–5825.

240. Kaiserhan D. The intestinal epithelial cell: a nonprofessional antigen-presenting cell. Immunology 1983;49:451–456.

241. MacPherson GG, Liu LM. Dendritic cells and nonresponsiveness by treatment with anti-MCP-1. Immunology 1993;70:302–310.

242. Eynon EE, Parker DC. Small B cells as antigen-presenting cells in the uptake of mucosal antigens. Curr Top Microbiol Immunol 1999;236:34–53.

243. Fuchs RJ, Thomason AW. Dendritic cells and tolerance induction. Clin Exp Immunol 1996;105:397–402.

244. Viney JI, Mowat AM, O'Malley JM, Williamson E, Fanger NA. Expanding dendritic cells in vivo enhances the induction of oral tolerance. J Immunol 1998;160:5815–5825.

245. Khoury SJ, Lider O, Al-Sabagh A, Weiner HL. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. III. Synergistic effect of lipopolysaccharide. Cell Immunol 1982;131:302–310.

246. Robbien W, Puttonen E, Maasch HJ, Stix E, Wiln U. Clinical and immunological response to oral and subcutaneous immunotherapy with grass pollen extracts. A prospective study. Eur J Pediatr 1982;138:341–344.

247. Wortmann F. Oral hypersensitization of children with pollenosis or house dust asthma. Allergol Immunopathol 1977;5:15–26.

248. Hoyne GE, O’Hehir RE, DC Wraith, Thomas WR, Lamb JR. Inhibition of T cell and antibody responses to house dust mite allergen by ingestion of the dominant T cell epitope in naive and sensitized mice. J Exp Med 1993;178:1783–1788.

249. Hanson DG, Zay NM, Rawlings LA, Lynch JM. Inhibition of specific immune responses by feeding protein antigens. II. Effects of prior passive and active immunization. J Immunol 1979;122:2261–2266.

250. Staines NA, Harper N, Ward F, Thompson ESG, Bansal S. Arthritis: animal models of oral tolerance. Ann N Y Acad Sci 1996;778:297–305.

251. Czerkinsky C, et al. Cholera toxin B subunit as transmucosal carrier-delivery and immunomodulating system for induction of anti-infectious and anti-pathological immunity. Ann N Y Acad Sci 1996;778:185–193.

252. Sun JB, Rask C, Olsson T, Holmgren J. Czerkinsky C. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc Natl Acad Sci USA 1996;93:7196–7201.

253. Tarkowski A, Sun JB, Holmdahl R, Holmgren J. Czerkinsky C. Treatment of experimental autoimmune arthritis by nasal administration of a type II collagen-cholera toxin conjugate vaccine. Arthritis Rheum (In press).

254. Bergerot I, et al. A cholera toxin-insulin conjugate as oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci USA 1997;94:4610–4614.

255. Ma D, Mellon J, Niederkorn JY. Conditions affecting enhanced corneal allograft survival by oral immunization. Invest Ophthalmol Vis Sci 1998;39:1835–1846.

256. Tamura S, Hatori E, Tsuruhara T, Aizawa C, Kurata T. Suppression of delayed-type hypersensitivity and IgE antibody responses to ovalbumin by intranasal administration of Escherichia coli heat-labile enterotoxin B subunit-conjugated ovalbumin. Vaccine 1997;15:225–229.

257. Julia V, Rassoulzadegan M, Gaichhausen. Resistance to Leishmania major induced by tolerance to a single antigen. Science 1996;274:421–423.

258. McSorley SJ, Rask C, Pichot R, Julia V, Czerkinsky C, Gaichhausen, N. Selective tolerization of Th1-like cells after nasal administration of a cholera toxin-LACK conjugate. Eur J Immunol 1998;28:44–430.

259. Sun JB, et al. Intranasal administration of a Schistosoma mansoni glutathione S-transferase-cholera toxoid conjugate vaccine elicits antiparasitic and antipathological immunity in mice. J Immunol 1999;163:1045–1052.

260. Arakawa T, Yu J, Chong DK, Hough J, Engen PC, Langridge WH. A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat Biotechnol 1998;16:934–938.

261. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999;5:387–391.
This document is a scanned copy of a printed document. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material.